Hyperactivated lipid nanoparticles

By using lipid nanoparticles containing LPC and TLR7/8 agonists to contact dendritic cells, the shortcomings of existing vaccines in T cell response were overcome, achieving highly efficient DC hyperactivation and immune stimulation.

CN118922179APending Publication Date: 2024-11-08CORNER THERAPEUTICS INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380029973.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-10-18
Filing Date
2023-02-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing LNP-based mRNA vaccines and protein subunit vaccines have limited effectiveness in inducing antigen-specific T cell responses, and traditional DC activation methods are difficult to achieve efficient IL-1β secretion and long-lived T cell responses.

Method used

Lipid nanoparticles (LNPs) containing lysophosphatidylcholine (LPC) and TLR7/8 agonists are used to contact dendritic cells to hyperactivate DCs, promote IL-1β secretion without causing pyroptosis, and enhance T cell responses.

Benefits of technology

It significantly increased the hyperactivation level of mammalian dendritic cells, enhanced IL-1β secretion and T cell response, and achieved a more efficient immune stimulation effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922179A_ABST
    Figure CN118922179A_ABST
Patent Text Reader

Abstract

The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one additional lipid, and the use of the lipid nanoparticles in hyperactivity of mammalian dendritic cells, such as human dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising LPC and at least one additional lipid wherein the composition comprises one or more of a pathogen-recognizing receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for producing and using the compositions.
Need to check novelty before this filing date? Find Prior Art

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 417,282, filed on October 18, 2022, and U.S. Provisional Patent Application No. 63 / 307,569, filed on February 7, 2022, each of which is incorporated herein by reference in its entirety. Technical Field

[0002] The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one additional lipid, and the use of the lipid nanoparticles in hyperactivating mammalian dendritic cells (such as human dendritic cells). The present disclosure also relates to compositions comprising lipid nanoparticles comprising LPC and at least one additional lipid, wherein the compositions comprise one or more of a pathogen recognition receptor agonist, an antigen, and a mammalian cell, and methods for producing and using the compositions. Background Art

[0003] Lipid nanoparticles (LNPs) have become an important vaccine delivery tool, especially in the context of mRNA vaccines. Although LNP-based mRNA vaccines as well as protein subunit vaccines are effective in inducing antigen-specific antibody responses, they generally exhibit limited antigen-specific T cell responses.

[0004] Dendritic cells (DC) provide several signals to T cells, which are important for establishing appropriate T cell responses. The type and size of the signal depend on the activation state of DC (Zhivaki and Kagan, Nature Reviews Immunology, 22: 322-339, 2022). Original DC is a quiescent cell with the ability to absorb antigens. Active DC not only has the ability to absorb antigens, but also has the enhanced ability to present peptide fragments of antigens on major histocompatibility complex molecules. In addition, active DC has increased expression of co-stimulatory molecules for stimulating T cells. Superactive DC shares activity with its active DC counterparts, and also obtains the ability to super migrate to lymph nodes and secrete IL-1β. Like superactive DC, pyroptotic DC secretes high levels of IL-1β. However, pyroptotic DC is a dead cell that rapidly loses its T cell stimulation ability. When DCs are matured using lipopolysaccharide (LPS) containing pathogen-associated molecular pattern (PAMP) molecules and damage-associated molecular pattern (DAMP) molecules such as PGPC (1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine), they secrete IL-1β without undergoing pyroptosis, characterizing these cells as hyperactive (Zanoni et al., Science, 352(6290):1232-1236, 2016).

[0005] Therefore, it is desirable to include in vaccines LNP formulations that have the ability to superactivate dendritic cells. In particular, there is a need in the art for LNPs that have the ability to induce IL-1β secretion and enhance the production of long-lived T cell responses. Summary of the invention

[0006] The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one additional lipid, and the use of the lipid nanoparticles in hyperactivating mammalian dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising LPC and at least one additional lipid, wherein the composition further comprises one or more of a pathogen recognition receptor agonist, an antigen, and a mammalian dendritic cell, and methods for producing and using the composition.

[0007] In particular, the present disclosure provides compositions comprising isolated lysophosphatidylcholine (LPC) with a single acyl chain, at least one additional lipid and a TLR7 / 8 agonist, wherein the acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, and the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the at least one additional lipid is selected from ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structural lipids and mixtures thereof. In some embodiments, the acyl chain is a C18-C22 acyl chain, a C21-C24 acyl chain or a C22 acyl chain. In some embodiments, the compositions further comprise an antigen and / or a dendritic cell.

[0008] In some aspects, the disclosure provides a composition comprising an isolated lysophosphatidylcholine (LPC) with a single acyl chain, at least one additional lipid and an antigen, wherein the acyl chain is a C21-C24 acyl chain, and the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the at least one additional lipid is selected from an ionizable lipid, a cationic lipid, an additional phospholipid, a pegylated lipid, a structural lipid and a mixture thereof. In some embodiments, the composition further comprises a dendritic cell and / or a TLR7 / 8 agonist.

[0009] In some aspects, the present disclosure provides a composition comprising an isolated lysophosphatidylcholine (LPC) with a single acyl chain, at least one additional lipid and a dendritic cell, wherein the acyl chain is a C21-C24 acyl chain, and the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the at least one additional lipid is selected from an ionizable lipid, a cationic lipid, an additional phospholipid, a pegylated lipid, a structural lipid and a mixture thereof. In some embodiments, the composition further comprises a TLR7 / 8 agonist and / or an antigen.

[0010] In some embodiments of the foregoing aspects, the antigen is present in a biological sample obtained from an individual. In some embodiments, the biological sample comprises a biopsy. In some embodiments, the biological sample comprises a cell. In other embodiments, the biological sample does not include a cell. In some embodiments, the biological sample comprises pus from an abscess. In some embodiments, the antigen comprises a protein antigen. In some embodiments, the antigen comprises a tumor antigen. In some embodiments, the tumor antigen comprises a synthetic or recombinant neoantigen. In some embodiments, the tumor antigen comprises a tumor cell lysate. In some embodiments, the antigen comprises a microbial antigen, and the microbial antigen comprises one or more of a viral antigen, a bacterial antigen, a protozoan antigen, and a fungal antigen. In some embodiments, the microbial antigen comprises a purified or recombinant surface protein. In some embodiments, the microbial antigen comprises an inactivated whole virus.

[0011] In some embodiments, the composition does not include LPS or MPLA. In some embodiments, the composition does not include oxPAPC or oxPAPC species. In some embodiments, the composition does not include HOdiA-PC, KOdiA-PC, HOOA-PC, KOOA-PC and / or PGPC. In some embodiments, the composition does not include isolated mRNA. In some embodiments, the composition does not include a surfactant (e.g., poloxamer). In some embodiments, the composition does not include poloxamer 407 (KP407), poloxamer 188 (KP188) and / or Pluronic P123 (P123).

[0012] In some embodiments, the composition further comprises an adjuvant, wherein the adjuvant comprises an aluminum salt adjuvant, a squalene-in-water emulsion, a saponin, or a combination thereof.

[0013] In some embodiments, the disclosure provides a pharmaceutical preparation comprising the composition of any of the aforementioned aspects and a pharmaceutically acceptable excipient. In some embodiments, the preparation does not include a surfactant (e.g., poloxamer). In some embodiments, the preparation does not include poloxamer 407 (KP407), poloxamer 188 (KP188) and / or Pluronic P123 (P123).

[0014] In other aspects, the present disclosure provides a method for producing superactivated dendritic cells, the method comprising contacting the dendritic cells with an effective amount of a composition to produce superactivated dendritic cells, the composition comprising isolated lysophosphatidylcholine (LPC) with a single C13-C22 acyl chain or a C13-C24 acyl chain, at least one additional lipid, and a TLR7 / 8 agonist, wherein the superactivated dendritic cells secrete IL-1β without undergoing pyroptosis, and the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the at least one additional lipid is selected from ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structural lipids, and mixtures thereof. In some embodiments, the dendritic cells are contacted ex vivo with a composition or pharmaceutical formulation of any of the foregoing embodiments. In other embodiments, the dendritic cells are contacted in vivo with the pharmaceutical formulation comprising the composition of any of the foregoing embodiments. In some aspects, the present disclosure provides a pharmaceutical formulation comprising a plurality of the hyperactivated dendritic cells produced according to the foregoing embodiments and a pharmaceutically acceptable excipient. In some embodiments, the plurality comprises at least 10 3 , 10 4 , 10 5 , 10 6 , 10 7 or 10 8 A super-activated DC.

[0015] In other aspects, the present disclosure provides a composition comprising an isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a pathogen recognition receptor (PRR) agonist, wherein the acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, and the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the at least one additional lipid is selected from ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structural lipids and mixtures thereof. In some embodiments, the PRR agonist is an agonist of a toll-like receptor (TLR), a NOD-like receptor (NLR), a RIG-I-like receptor (RLR) or a C-type lectin receptor (CLR). In some embodiments, the PRR agonist is an agonist of a cytoplasmic DNA sensor (CDS) or an IFN gene stimulator (STING). In some embodiments, the PRR agonist comprises a TLR7 / 8 agonist. In some embodiments, the composition further comprises an antigen and / or dendritic cells.

[0016] In some embodiments of the foregoing aspects, the acyl chain is a C21-C24 acyl chain. In some embodiments, the acyl chain is a C22 acyl chain. In some embodiments, the acyl chain is fully saturated. In some embodiments, the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)].

[0017] In some embodiments of the aforementioned aspects, the TLR7 / 8 agonist is a small molecule with a molecular weight of 900 Daltons or less. In some embodiments, the TLR7 / 8 agonist includes an imidazoquinoline compound. In some embodiments, the TLR7 / 8 agonist includes resiquimod (R848). In some embodiments, the LPC includes LPC (22:0), and the TLR7 / 8 agonist includes resiquimod (R848).

[0018] The present disclosure further provides a composition for superactivating human dendritic cells, the composition comprising an isolated lysophosphatidylcholine (LPC) compound having a single acyl chain, at least one additional lipid, and a pathogen recognition receptor (PRR) agonist, wherein the acyl chain is a C22 acyl chain, the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP), and the composition is effective for achieving a higher level of dendritic cell superactivation than a comparative composition comprising a comparative compound instead of the LPC. In some embodiments, the at least one additional lipid is selected from an ionizable lipid, a cationic lipid, an additional phospholipid, a pegylated lipid, a structural lipid, and a mixture thereof. In some embodiments, the superactivation occurs in vitro or ex vivo. In other embodiments, the superactivation occurs in vivo. In some embodiments, the higher level of dendritic cell hyperactivation includes inducing IL-1β secretion from the mammalian (e.g., human) dendritic cells in vitro at the following level, when contacted with the composition comprising the LPC and the PRR agonist, the level is at least 2, 3 or 4 times higher than when contacted with the comparative composition comprising the comparative compound and the PRR agonist, wherein the PRR agonist is LPS. In some embodiments, the concentration of the LPC and the concentration of the comparative compound are the same concentration, optionally in the range of from about 10 μM to about 80 μM, and the LPS is present in both the composition and the comparative composition at a concentration of 1 μg / ml. In some embodiments, the higher level of dendritic cell hyperactivation includes the following lipid activity index of IL-1β secretion from the mammalian (e.g., human) dendritic cells of the composition comprising the LPC and the PRR agonist, the lipid activity index is at least 4, 5 or 6 times higher in activity units than the comparative composition comprising the comparative compound and the PRR agonist. In some embodiments, the comparative compound is PGPC. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1A-1B IL-1β secretion by canine peripheral blood mononuclear cells (PBMCs) two days after activation with the indicated stimuli is shown as total concentration ( Figure 1A ) and the fold change of each donor relative to R848 alone ( Figure 1B The results demonstrated that 22:0LYSO PC, when combined with R848, was able to stimulate canine PBMCs to secrete IL-1β at levels comparable to or higher than DAMPs such as PGPC or LPS and aluminum adjuvants. Figure 1C The relative viability of canine PBMCs two days after activation with the indicated stimuli is shown. The results demonstrate that canine PBMCs remain viable after treatment with 22:0LYSO PC.

[0020] Figure 2A-2B IL-1β secretion by human PBMCs two days after activation with the indicated stimuli is shown as total concentration ( Figure 2A ) and the fold change of each donor relative to R848 alone ( Figure 2B ). The results demonstrated that 22:0LYSOPC, when combined with R848, was able to stimulate IL-1β secretion from human PBMCs at levels comparable to or higher than DAMPs such as PGPC or LPS and aluminum adjuvants. Figure 2C The relative viability of human PBMCs two days after activation with the indicated stimuli is shown. The results demonstrate that human PBMCs remain viable after treatment with 22:0LYSO PC.

[0021] Figure 3A-3B Shown are IFNγ ( Figure 3A ) and TNFα( Figure 3B ) secretion, shown as the fold change for each donor relative to R848 alone. The results demonstrate that when combined with R848, 22:0LYSOPC is able to stimulate human PBMCs to secrete other immunostimulatory cytokines at levels comparable to or higher than DAMPs (such as PGPC) or LPS and aluminum adjuvants.

[0022] Figure 4 It is shown that including different concentrations of 22:0Lyso PC in lipid nanoparticles (LNPs) does not affect the size of the resulting LNPs. In this figure, the vehicle controls for LNP 2 and LNP 3 are the same.

[0023] Figure 5A Quantification of 22:0Lyso PC inclusion in GenVoy LNPs is shown. Figure 5B Shown is the quantification of 22:0Lyso PC inclusion in LNPs containing ionizable lipids. Figure 5C Shown is the quantification of 22:0Lyso PC inclusion in LNPs lacking ionizable lipids. Figure 5D showed that increasing 22:0Lyso PC import resulted in increased loading of 22:0Lyso PC in LNPs.

[0024] Fig. 6A Shown are the viability of monocyte-derived dendritic cells (moDCs) cultured in the presence or absence of LNPs and in the presence or absence of pathogen-associated molecular pattern-containing molecules (PAMPs). Figure 6B IL-1β secretion by moDCs cultured in the presence or absence of LNPs and in the presence or absence of PAMPs is shown. Figure 6A-6BThe PAMP utilized in the assay was resiquimod (R848), a TLR7 / 8 agonist. When present, 22:0Lyso PC was included at a concentration of 82.5 μM.

[0025] Fig. 7A It was shown that 22:0Lyso PC in PBS had a large diameter and a wide range of particle sizes. Figure 7B It was shown that 22:0Lyso PC loaded into LNPs resulted in smaller particle size with increased uniformity.

[0026] Figure 8A-8D It was shown that 22:0Lyso PC LNPs induced hyperactivation of murine bone marrow-derived dendritic cells (BMDCs). Fig. 8A Shown are the viability of BMDCs 48 hours after treatment with various formulations, as measured using a cell titer glow assay. Data presented are relative to R848 treated cells. Figure 8B IL-6 secretion by BMDCs 48 hours after treatment with various formulations is shown, and Figure 8C Shown are IL-1β secretion by BMDCs 48 hours after treatment with various formulations, as measured by ELISA. Means and SD are shown and represent three replicates from one experiment. Fig.8D The absolute number of CFSE+CD11c+MHC-II+DC in draining lymph nodes is shown, as measured by flow cytometry. BMDC were treated with various formulations for 24 hours prior to CFSE staining and injection. Unpaired t-test was used. Mean values ​​and SD are shown, and they represent four mice from one experiment. DETAILED DESCRIPTION

[0027] The present disclosure relates to lipid nanoparticles (LNPs) comprising a lysophosphatidylcholine (LPC) compound and at least one additional lipid, and the use of the lipid nanoparticles in super-activated mammalian dendritic cells. The present disclosure also relates to compositions comprising LNPs, wherein the LNPs comprise LPCs and at least one additional lipid, wherein the compositions further comprise one or more of a pathogen recognition receptor agonist, an antigen, and a mammalian dendritic cell, and methods for producing and using the compositions. In some embodiments, the dendritic cells are human dendritic cells. In other embodiments, the dendritic cells are non-human dendritic cells. In some embodiments, the non-human dendritic cells are not rodent dendritic cells. In some embodiments, the at least one additional lipid is selected from ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structural lipids, and mixtures thereof.

[0028] In some embodiments of the present disclosure, the LNP of the composition is rich in particles (liposomes) having a lipid bilayer relative to particles (micelles) having a single lipid layer. In particular, in some embodiments, the LNP comprises liposomes and has almost no micelles. General Techniques and Definitions

[0029] The practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art.

[0030] As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural referents unless otherwise indicated. For example, "an" excipient includes one or more excipients.

[0031] As used herein, the phrase "comprising" is open ended, indicating that such embodiments may include additional elements. In contrast, the phrase "consisting of is closed ended, indicating that such embodiments do not include additional elements (except for trace impurities). The phrase "consisting essentially of is partially closed ended, indicating that such embodiments may further include elements that do not substantially change the basic characteristics of such embodiments.

[0032] As used herein, the term "about" with respect to a value encompasses from 90% to 110% of that value (eg, a molecular weight of about 900 Daltons refers to molecular weights from 810 Daltons to 990 Daltons).

[0033] An "effective amount" or "sufficient amount" of a substance is an amount sufficient to achieve a beneficial or desired result, including a clinical result, and thus, the "effective amount" depends on the context in which it is used. For example, in the case of administration of an immunogenic composition, an effective amount contains enough antigen and one or both of a lysophosphatidylcholine (LPC) compound and a PRR agonist to stimulate an immune response (e.g., antigen-reactive antibodies and / or cellular immune responses) to the antigen.

[0034] The terms "individual" and "subject" refer to mammals. "Mammals" include, but are not limited to, humans, non-human primates (e.g., monkeys), livestock, sports animals, rodents (e.g., mice and rats), and pets (e.g., dogs and cats). In some embodiments, the subject is a human patient, such as a human patient suffering from cancer and / or an infectious disease.

[0035] The term "dose" as used herein with reference to an immunogenic composition refers to the measured portion of the immunogenic composition that a subject takes (is administered or receives) at any one time.

[0036] As used herein, the terms "isolated" and "purified" refer to a material that is removed from at least one component with which it was originally associated during its production (e.g., removed from its original environment). As an example, when used with respect to LPC, an isolated LPC is at least 90%, 95%, 96%, 97%, 98% or 99% pure, as determined by thin layer chromatography or gas chromatography. As a further example, when used with respect to a recombinant protein, an isolated protein refers to a protein that has been removed from the culture medium of the host cells in which the protein was produced. Additionally, when used with respect to a synthetic compound, an isolated compound or purified compound has been removed from the reaction mixture from which it was synthesized.

[0037] The terms "pharmaceutical formulation" and "pharmaceutical composition" refer to preparations that are in a form that permits the biological activity of the active ingredient to be effective, and that contain no additional components that are unacceptably toxic to a subject to which the formulation or composition is administered. Such formulations or compositions are intended to be sterile.

[0038] As used herein, "excipient" includes pharmaceutically acceptable excipients, carriers, vehicles or stabilizers that are not toxic to cells or mammals exposed thereto at the dosages and concentrations employed. Typically, a physiologically acceptable excipient is a pH buffered aqueous solution.

[0039] The term "antigen" refers to a substance that is recognized and specifically bound by an antibody or T cell antigen receptor. Antigens may include peptides, polypeptides, proteins, glycoproteins, polysaccharides, complex carbohydrates, sugars, gangliosides, lipids, and phospholipids; portions thereof and combinations thereof. When present in the compositions of the present disclosure, the antigen may be synthetic or isolated from nature. Antigens suitable for administration in the methods of the present disclosure include any molecule capable of eliciting an antigen-specific B cell or T cell response. Haptens are included within the scope of "antigens." "Haptens" are low molecular weight compounds that are not immunogenic in themselves but are immunogenic when conjugated to a generally larger immunogenic molecule (carrier).

[0040] "Polypeptide antigens" may include purified natural peptides, synthetic peptides, recombinant peptides, crude peptide extracts, or peptides in partially purified or unpurified active states (such as peptides as part of attenuated or inactivated viruses, microorganisms or cells) or fragments of such peptides. The length of a polypeptide antigen is preferably at least eight amino acid residues.

[0041] The term "agonist" is used in its broadest sense and includes any molecule that activates signal transduction through a receptor. In some embodiments, the agonist binds to a receptor. For example, a TLR8 agonist binds to a TLR8 receptor and activates the TLR8 signal transduction pathway.

[0042] "Alkyl" refers to a monovalent saturated aliphatic hydrocarbon group. Cx alkyl refers to an alkyl group having x carbon atoms. Cx-Cy alkyl or Cx-y alkyl refers to an alkyl group having x and y carbon atoms (including the end value).

[0043] "Alkylene" refers to a divalent saturated aliphatic hydrocarbon group.

[0044] "Alkenyl" refers to a monovalent hydrocarbon group having at least one double bond (>C=C<). Cx alkenyl refers to an alkenyl group having x carbon atoms. Cx-Cy alkenyl or Cx-y alkenyl refers to an alkenyl group having between x and y carbon atoms (inclusive).

[0045] "Stimulation" of a response or parameter includes initiating and / or enhancing the response or parameter when compared to otherwise identical conditions except for the parameter of interest or alternatively compared to another condition (e.g., TLR signaling increases in the presence of a TLR agonist compared to the absence of a TLR agonist). For example, "stimulation" of an immune response means an increase in a response. Depending on the parameter measured, the increase can be from 2 times to 2,000 times or from 5 times to 500 times or more, or from 2, 5, 10, 50 or 100 times to 500, 1,000, 2,000, 5,000 or 10,000 times.

[0046] In contrast, "inhibition" of a response or parameter includes reducing and / or inhibiting the response or parameter when compared to conditions that are otherwise identical except for the parameter of interest, or alternatively compared to another condition (e.g., a reduction in abnormal cell proliferation following administration of a composition comprising an LPC compound and one or more of a pathogen recognition receptor agonist, an antigen, and human dendritic cells, compared to administration of a placebo composition or no treatment). For example, "inhibition" of an immune response means a reduction in the response. Depending on the parameter being measured, the reduction can be from 2-fold to 2,000-fold or from 5-fold to 500-fold or more, or from 2, 5, 10, 50, or 100-fold to 500, 1,000, 2,000, 5,000, or 10,000-fold.

[0047] The relative terms "higher" and "lower" refer to a measurable increase or decrease in a response or parameter, respectively, when compared to a condition that is otherwise identical except for the parameter of interest, or alternatively compared to another condition. For example, "higher levels of DC hyperactivation" means that the level of DC hyperactivation as a result of a treatment condition (comprising an LPC compound of the present disclosure) is at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 times the level of DC hyperactivation as a result of a control condition (e.g., no LPC, PGPC, oxPAPC, etc.). Similarly, "lower levels of DC hyperactivation" means that the level of DC hyperactivation as a result of a treatment condition (comprising an LPC compound of the present disclosure) is at least 1 / 2, 1 / 3, 1 / 4, 1 / 5, 1 / 6, 1 / 7, 1 / 8, 1 / 9, or 1 / 10 of the level of DC hyperactivation as a result of a control condition (e.g., no LPC, PGPC, oxPAPC, etc.). In some embodiments, the control condition includes a comparison compound instead of the LPC of the treatment condition.

[0048] As used herein, the term "immunization" refers to the process of increasing a mammalian subject's response to an antigen and thereby improving its ability to resist or overcome infection and / or resist disease.

[0049] The term "vaccination" as used herein refers to the introduction of a vaccine into the body of a mammalian subject.

[0050] "Adjuvant" refers to a substance that, when added to a composition comprising an antigen, enhances or strengthens the immune response of a mammalian recipient to the antigen upon exposure.

[0051] The term "treating" or "treatment" disease refers to the implementation of such a scheme, which may include administering one or more therapeutic agents to an individual (human or other individual) in an effort to obtain beneficial or desired results, including clinical results, in the individual. Beneficial or desired clinical results include, but are not limited to, alleviating or improving one or more signs or symptoms of the disease, reducing the extent of the disease, stabilizing (i.e., not worsening) the disease state, preventing the spread of the disease, delaying or slowing the progression of the disease, improving or alleviating the disease state, and alleviating (whether partial or complete). "Treatment" can also mean extending the survival period compared to the expected survival period of an individual who has not received treatment. In addition, "treating" and "treatment" can occur by administering one dose of one or more therapeutic agents, or can occur when administering a series of doses of one or more therapeutic agents. "Treatment" or "treatment" does not require complete alleviation of signs or symptoms, and does not require cure, and particularly includes schemes that only have a palliative effect on an individual. To "alleviate" a disease or disorder means to reduce the extent and / or undesirable clinical manifestations of the disease or disorder, and / or to slow the course of progression of the disease or disorder, as compared to the expected untreated outcome. I. Lysophosphatidylcholine compounds

[0052] "Lysophosphatidylcholine" (LPC) or "lysophosphatidylcholine molecule" refers to a glycerol molecule that carries a phosphorylcholine group on the hydroxyl group of glycerol and an acyl group on one of the other two hydroxyl groups of glycerol. The remaining hydroxyl groups are unsubstituted.

[0053] In some embodiments, the isolated lysophosphatidylcholine (LPC) having a single acyl chain has the following form:

[0054] In some embodiments, the isolated lysophosphatidylcholine (LPC) having a single acyl chain has the following form:

[0055] The alkyl or alkenyl chain together with the carbonyl carbon forms an acyl chain that is one carbon atom longer than the alkyl or alkenyl chain. For example, a (C23 alkyl)-C(=O)-group forms a C24 acyl chain. Thus, when the group "(alkyl or alkylene)" is a C12-C23 alkyl (such as a C12-C19 alkyl or a C20-C23 alkyl), the (C12-C23 alkyl)-C(=O)-group forms a C13-C24 acyl chain (such as a C13-C20 acyl chain or a C21-C24 acyl chain). When the group "(alkyl or alkylene)" is a C12-C23 alkenyl (such as a C12-C19 alkenyl or a C20-C23 alkenyl), the (C12-C23 alkenyl)-C(=O)-group forms a C13-C24 acyl chain (such as a C13-C20 acyl chain or a C21-C24 acyl chain). Acyl chains may be referred to as saturated acyl or unsaturated acyl to distinguish between alkyl-containing acyl and alkenyl-containing acyl. Standard delta notation or omega notation may be used to indicate the position of one or more double bonds in an unsaturated acyl chain.

[0056] The lysophosphatidylcholine (LPC) compounds of the present disclosure have a single acyl chain, wherein the acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain. In some embodiments, the acyl chain is a C18-C22 acyl chain or a C21-C24 acyl chain. In some preferred embodiments, the acyl chain is a C22 acyl chain. The names and structures of the exemplary LPC compounds included in the LNPs of the present disclosure and their Chemical Abstracts Service (CAS) registration numbers are listed as compounds #30-#43, optionally #30-#42 of Table 1 of International Application No. PCT / US2022 / 071664 (which is incorporated herein by reference). Several methods for synthesizing lysophospholipids are known (see, e.g., D'Arrigo et al., "Synthesis of lysophospholipids," Molecules, 15(3): 1354-77, 2010; and Yang et al., "Lysophosphatidylcholine synthesis by lipase-catalyzed ethanolysis," J Oleo Sci., 64(4): 443-7, 2015, and references cited therein). In addition, many lysophospholipids are commercially available. II. Pathogen Recognition Receptor Agonists

[0057] The compositions and methods of the present disclosure may further include a pathogen recognition receptor (PRR) agonist. In some embodiments, the PRR agonist includes an agonist of a toll-like receptor (TLR), a NOD-like receptor (NLR), a RIG-I-like receptor (RLR), or a C-type lectin receptor (CLR). In other embodiments, the PRR agonist includes a cytoplasmic DNA sensor (CDS) or an IFN gene stimulator (STING). In some embodiments, the PRR agonist includes a TLR7 / 8 agonist. A. TLR7 / 8 agonists

[0058] The term "TLR7 / 8 agonist" as used herein refers to an agonist of TLR7 and / or TLR8. In one aspect, the TLR7 / 8 agonist is a TLR7 agonist. In another aspect, the TLR7 / 8 agonist is a TLR8 agonist. In a further aspect, the TLR7 / 8 agonist is an agonist of both TLR7 and TLR8. The TLR7 / 8 agonist of the present disclosure is suitable for superactivating human dendritic cells in the presence of LPC.

[0059] In some aspects, TLR7 / 8 agonists are small molecules. In some embodiments, TLR7 / 8 agonists are small molecules or salts thereof having a molecular weight of 900 Daltons or less. That is, small molecule TLR7 / 8 agonists are not macromolecules that can be controlled by the US FDA Biologics Evaluation and Research Center (USFDA's Center forBiologics Evaluation and Research) like recombinant proteins or synthetic oligonucleotides. Instead, small molecule TLR7 / 8 agonists can be controlled by the FDA Drug Evaluation and Research Center (FDA's Center for Drug Evaluation and Research). In some embodiments, the molecular weight of the small molecule is from about 90 to about 900 Daltons. In some embodiments, TLR7 / 8 agonists include imidazoquinoline compounds. In some preferred embodiments, TLR7 / 8 agonists include resiquimod (R848). B. Other PRR agonists

[0060] In some aspects, pathogen recognition receptor (PRR) agonists include toll-like receptor (TLR) agonists, provided that the TLR agonists do not include TLR7 / 8 agonists. In some embodiments, TLR agonists include agonists of one or more of TLR2, TLR3, TLR4, TLR5, TLR9 and TLR13. In some embodiments, the PRR agonist is a TLR2 / 6 agonist, such as Pam2CSK4. In other embodiments, the TLR agonist is a TLR4 agonist, such as monophosphoryl lipid A (MPLA). However, in preferred embodiments, the TLR agonist is not an agonist of TLR2, TLR4 and / or TLR9. For example, in preferred embodiments, the TLR9 agonist is not a TLR4 ligand, such as LPS (endotoxin).

[0061] In other aspects, the PRR agonist comprises a NOD-like receptor (NLR) agonist. In further aspects, the PRR agonist comprises a RIG-I-like receptor (RLR) agonist. In additional aspects, the PRR agonist comprises a C-type lectin receptor (CLR) agonist. In still further aspects, the PRR agonist comprises a CDS agonist or a STING agonist. III. Antigens

[0062] The compositions and methods of the present disclosure may further include an antigen. In some embodiments, the antigen includes a protein antigen. The terms "polypeptide" and "protein" are used interchangeably herein to refer to a protein antigen comprising a peptide chain of at least 8 amino acids in length. In some embodiments, the length of the protein antigen is from 8 to 1800 amino acids, 9 to 1000 amino acids, or 10 to 100 amino acids. In some embodiments, the antigen includes a synthetic protein or a recombinant protein. In other embodiments, the antigen includes a protein purified from a biological sample. The polypeptide may be post-translationally modified, such as modified by phosphorylation, hydroxylation, sulfonation, palmitoylation, and / or glycosylation.

[0063] In some embodiments, antigen is a tumor antigen comprising an amino acid sequence of at least one full-length protein or a fragment thereof. In some embodiments, tumor antigens comprise amino acid sequences or fragments thereof from oncoproteins. In some embodiments, mammalian antigens are neoantigens or are encoded by genes comprising mutations relative to genes present in normal cells from mammalian subjects. Neoantigens are considered to be particularly useful in enabling T cells to distinguish between cancer cells and non-cancerous cells (see, for example, Schumacher and Schreiber, Science, 348: 69-74, 2015). In other embodiments, tumor antigens include viral antigens, such as antigens of oncoviruses.

[0064] In some embodiments, the tumor antigen is a fusion protein comprising two or more polypeptides, wherein each polypeptide comprises an amino acid sequence from a different tumor antigen or a non-continuous amino acid sequence from the same tumor antigen. In some of these embodiments, the fusion protein comprises a first polypeptide and a second polypeptide, wherein each polypeptide comprises a non-continuous amino acid sequence from the same tumor antigen.

[0065] In some embodiments, the antigen is a microbial antigen. In some embodiments, the microbial antigen includes a viral antigen, a bacterial antigen, a protozoan antigen, a fungal antigen, or a combination thereof. In some embodiments, the microbial antigen includes a surface protein or other antigenic subunit of a microorganism. In other embodiments, the microbial antigen includes an inactivated or attenuated microorganism. For example, the microbial antigen may include an inactivated virus, such as a chemically or genetically inactivated virus. Alternatively, the microbial antigen may include a virus-like particle.

[0066] In some embodiments, the antigen may be present in a biological sample obtained from an individual (e.g., a human patient). For example, the antigen may include a cancer cell. In another aspect, the antigen may include a microbial-infected cell, such as a virus-infected cell. IV. Dendritic Cells

[0067] The compositions and methods of the present disclosure may further include dendritic cells (DC), which are antigen presenting cells that are believed to bridge the innate and adaptive immune systems of mammals. In preferred embodiments, the DC are subset-1 conventional DC (cDC1, formerly known as myeloid DC1), in contrast to plasmacytoid DC (pDC).

[0068] In some embodiments, DC is a superactive DC expressing high levels of CD40 and IL-12p70. As used herein, the term "superactive dendritic cell" refers to a cell state in which DC is able to secrete IL-1β while maintaining cell viability (e.g., without undergoing pyroptosis). In this way, superactivated dendritic cells are able to stimulate robust T cell immunity (Figure 1), which apparently combines the benefits of activated dendritic cells with pyroptotic dendritic cells (Zhivaki et al., Cell Reports, 33 (7), 2020, 108381). V. Additional lipids

[0069] The compositions and methods of the present disclosure include at least one other lipid, wherein the LPC and the at least one other lipid are part of lipid nanoparticles (LNP). In some embodiments, the at least one other lipid includes ionizable lipids, cationic lipids, other phospholipids, pegylated lipids, structural lipids or mixtures thereof. In some embodiments, the LNP includes a first phospholipid (lysophosphatidylcholine [LPC:C13-C24] with a single C13-C24 acyl chain), an ionizable lipid, a second phospholipid, a pegylated lipid and a structural lipid. The structure of the other lipids suitable for use in the compositions and methods of the present disclosure is as follows (reproduced from Hou et al., Nature Review Materials, 6: 1078-1094, Figure 2 of 2021).

[0070] In some embodiments, the at least one additional lipid comprises one or both of an additional phospholipid and a structural lipid, optionally wherein the additional phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), and the structural lipid comprises cholesterol. In some embodiments, the at least one additional lipid comprises or further comprises a pegylated lipid, optionally wherein the pegylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoylglycerol [DMG]. In some embodiments, at least one additional lipid includes or further includes an ionizable lipid, optionally wherein the ionizable lipid includes (6Z,9Z,28Z,31Z)-heptatriacontane-6,9,28,31-tetraen-19-yl 4(dimethylamino)-butyrate (also known as 4-(dimethylamino)-butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecadien-1-yl ester (DLin-MC3-DMA) or an analog or derivative thereof. VI. Pharmaceutical Preparations

[0071] Some compositions of the present disclosure are pharmaceutical formulations comprising a pharmaceutically acceptable excipient and lipid nanoparticles (LNPs) comprising an LPC compound and at least one additional lipid. In some embodiments, the at least one additional lipid is selected from ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structural lipids, and mixtures thereof. In some embodiments, the pharmaceutical formulation further comprises a PRR agonist, a dendritic cell, an antigen, an adjuvant, or any combination thereof. The pharmaceutical formulation of the present disclosure may be in the form of a solution or a suspension. Alternatively, the pharmaceutical formulation may be a dehydrated solid (e.g., a freeze-dried or spray-dried solid). The pharmaceutical formulation of the present disclosure is preferably sterile and preferably substantially free of endotoxin. The term "pharmaceutical formulation" is used interchangeably herein with the terms "pharmaceutical product" and "medicament". In some embodiments, the pharmaceutical formulation comprises various components in specific ratios based on the intended purpose of the formulation. A. Excipients

[0072] Pharmaceutically acceptable excipients of the present disclosure include, for example, solvents, buffers, tonicity adjusters, fillers, and preservatives (see, for example, Pramanick et al., Pharma Times, 45:65-77, 2013). In some embodiments, the pharmaceutical formulation may include an excipient that serves as one or more of a solvent, buffer, tonicity adjuster, and filler (e.g., sodium chloride in saline can serve as both an aqueous vehicle and a tonicity adjuster).

[0073] In some embodiments, the pharmaceutical formulation comprises an aqueous vehicle as a solvent. Suitable vehicles include, for example, sterile water, saline solution, phosphate-buffered saline, and Ringer's solution. In some embodiments, the composition is isotonic.

[0074] The pharmaceutical formulation may include a buffer. The buffer controls pH to inhibit degradation of the active agent during processing, storage and optionally reconstitution. Suitable buffers include, for example, salts, including acetate, citrate, phosphate or sulfate. Other suitable buffers include, for example, amino acids, such as arginine, glycine, histidine and lysine. The buffer may further include hydrochloric acid or sodium hydroxide. In some embodiments, the buffer maintains the pH of the composition in the range of 6 to 9. In some embodiments, the pH is greater than (lower limit) 6, 7 or 8. In some embodiments, the pH is less than (upper limit) 9, 8 or 7. That is, the pH is in the range of from about 6 to 9, wherein the lower limit is less than the upper limit.

[0075] The pharmaceutical composition may contain a tonicity adjuster. Suitable tonicity adjusters include, for example, dextrose, glycerol, sodium chloride, glycerol, and mannitol.

[0076] The pharmaceutical formulation may include fillers. Fillers are particularly useful when the pharmaceutical composition is to be lyophilized before administration. In some embodiments, fillers are protective agents that help stabilize the active agent and prevent degradation of the active agent during freezing or spray drying and / or during storage. Suitable fillers are sugars (monosaccharides, disaccharides and polysaccharides), such as sucrose, lactose, trehalose, mannitol, sorbitol, glucose and raffinose.

[0077] The pharmaceutical formulation may contain a preservative. Suitable preservatives include, for example, antioxidants and antimicrobial agents. However, in a preferred embodiment, the pharmaceutical formulation is prepared under sterile conditions and stored in a disposable container, and therefore does not need to contain a preservative.

[0078] The pharmaceutical compositions and other compositions of the present disclosure are generally free of surfactants (e.g., poloxamer). In particular, in some embodiments, the pharmaceutical compositions and other compositions are free of poloxamer 407 (KP407), poloxamer 188 (KP188) and / or Pluronic P123 (P123).

[0079] The pharmaceutical formulations of the present disclosure are suitable for parenteral administration. That is, the pharmaceutical formulations of the present disclosure are not intended for enteral administration (eg, not administered orally, gastrically, or rectally). B. Adjuvant

[0080] Pharmaceutically acceptable adjuvants of the present disclosure include, for example, aluminum salt adjuvants, squalene in water emulsions, saponins, or combinations thereof. In some embodiments, the adjuvant is an aluminum salt adjuvant selected from amorphous aluminum hydroxyphosphate sulfate, aluminum hydroxide, aluminum phosphate, potassium aluminum sulfate, and combinations thereof. In other embodiments, the adjuvant is a squalene in water emulsion, such as MF59 or AS03. In other embodiments, the adjuvant is a saponin, such as Quil A or QS-21, such as in AS01 or AS02. VII. Generation method

[0081] In some aspects, the disclosure relates to methods for preparing hyperactivated dendritic cells and methods for preparing immunogenic compositions.The immunogenic compositions are suitable for hyperactivating dendritic cells in vitro, ex vivo, or in vivo.

[0082] In one aspect, the present disclosure provides a method for producing superactivated dendritic cells (DCs), the method comprising contacting the dendritic cells with an effective amount of a composition to produce superactivated dendritic cells, the composition comprising isolated lysophosphatidylcholine (LPC) with a single acyl chain, at least one additional lipid, and a PRR agonist, wherein the superactivated dendritic cells secrete IL-1β without undergoing pyroptosis, and the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the at least one additional lipid is selected from ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structural lipids, and mixtures thereof. In some embodiments, DCs are isolated, while in other embodiments, DCs are present in biological samples obtained from mammalian subjects (such as human patients). In some embodiments, DCs are monocyte-derived DCs, preferably cDC1.

[0083] In a specific embodiment, the present disclosure provides a method for producing an immunogenic composition, the method comprising: a) optionally depleting a cell suspension prepared from a tumor of leukocytes to obtain a suspension enriched in tumor cells; b) lysing cells from the tumor cell-enriched suspension to obtain a tumor cell lysate; and c) contacting the tumor cell lysate with isolated lysophosphatidylcholine (LPC) with a single acyl chain, at least one additional lipid and a PRR agonist to obtain the immunogenic composition, wherein the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the at least one additional lipid is selected from ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structural lipids and mixtures thereof. In some embodiments, leukocytes are depleted from a cell suspension rich in tumor cells by contacting the suspension rich in tumor cells with antibodies specific for leukocytes. In some embodiments, leukocytes are depleted by contacting the suspension rich in tumor cells with anti-CD45 antibodies. In some embodiments, cells are lysed by a cell lysis method based on physical destruction (such as, but not limited to, mechanical lysis, liquid homogenization, ultrasonic treatment, freeze-thaw or manual grinding). In some preferred embodiments, cells are lysed by one or more freeze-thaw cycles.

[0084] In some embodiments of the above methods, the acyl chain of LPC is a C13-C22 acyl chain or a C13-C24 acyl chain. In some embodiments, the acyl chain of LPC is a C18-C22 acyl chain or a C18-C24 acyl chain. In some preferred embodiments, the acyl chain is fully saturated. In some preferred embodiments, the acyl chain of LPC is a C22 acyl chain. In some preferred embodiments, LPC is 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC (22:0)]. In some embodiments, the PRR agonist is a TLR7 / 8 agonist. In some preferred embodiments, the TLR7 / 8 agonist is an imidazoquinoline compound, which in a particularly preferred embodiment is resiquimod (R848). VIII. How to use

[0085] In some aspects, the present disclosure relates to methods of use of any of the compositions or formulations described herein. In some embodiments, the composition or formulation comprises an LPC compound and at least one additional lipid, wherein the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the at least one additional lipid is selected from ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structural lipids, and mixtures thereof. In some embodiments, the composition or formulation further comprises a PRR agonist, a dendritic cell, an antigen, an adjuvant, or any combination thereof. The method of use is suitable for a variety of uses involving stimulation of an immune response. In some embodiments, the method of use includes a method for treating cancer. In some embodiments, the method of use includes a method for inhibiting abnormal cell proliferation. In some embodiments, the method of use includes a method for treating an infectious disease. The method includes administering an effective amount of a formulation or composition described herein to an individual in need thereof to achieve a specific outcome. The individual is a mammalian subject, such as a human patient. In other embodiments, the individual is a non-human patient. In some embodiments, the individual is a canine patient. That is, in some embodiments, the method of use relates to clinical use, while in other embodiments, the method of use relates to preclinical and / or veterinary use. For preclinical use, the mammalian subject can be a non-human primate (e.g., a monkey or ape) or a rodent (e.g., a mouse or rat). For veterinary use, the mammalian subject can be a livestock (e.g., a cow), a sport animal (e.g., a horse), or a pet (e.g., a companion animal, such as a dog or a cat). A. Stimulate immune response

[0086] In short, the present disclosure provides methods for stimulating an immune response of an individual, the method comprising administering a composition or formulation described herein to an individual in an amount sufficient to stimulate an immune response of the individual. "Stimulating" an immune response (which can be used interchangeably with "eliciting" an immune response) means increasing an immune response, which can be produced by inducing a de novo immune response (e.g., as a result of an initial vaccination regimen) or enhancing an existing immune response (e.g., as a result of a booster vaccination regimen). In some embodiments, stimulating an immune response includes one or more of the group consisting of: stimulating cytokine production; stimulating B lymphocyte proliferation; stimulating interferon pathway-related gene expression; stimulating chemoattractant-related gene expression; and stimulating dendritic cell (DC) maturation. Methods for measuring the stimulation of an immune response are known in the art.

[0087] For example, the present disclosure provides a method for inducing an antigen-specific immune response in an individual by administering a composition or formulation as described herein to an individual in an amount sufficient to induce an antigen-specific immune response in the individual. In a preferred embodiment, the composition or formulation comprises an antigen. In some embodiments, the composition or formulation comprising the antigen is administered to an individual's tissue. The immune response may include one or both of an antigen-specific antibody response and an antigen-specific cytotoxic T lymphocyte (CTL) response. "Inducing" an antigen-specific antibody response means increasing the titer of an antigen-specific antibody to above a threshold level (such as a baseline titer or serum protection level before administration). "Inducing" an antigen-specific CTL response means increasing the frequency of antigen-specific CTLs found in peripheral blood to above the baseline frequency before administration.

[0088] The analysis of immune response (both qualitative and quantitative) can be performed by any method known in the art, including but not limited to measuring antigen-specific antibody production (including measuring specific antibody subclasses), activation of specific lymphocytes (such as B cells and helper T cells) populations, production of cytokines (such as IFN-α, IFN-γ, IL-6, IL-12) and / or release of histamine. The method for measuring antigen-specific antibody response includes enzyme-linked immunosorbent assay (ELISA). The activation of specific lymphocyte populations can be measured by proliferation assay and fluorescence activated cell sorting (FACS). The production of cytokines can also be measured by ELISA. In some embodiments, the method of stimulating immune response includes stimulating interleukin-1β (IL-1β) secretion, interferon-γ (IFN-γ) secretion and / or tumor necrosis factor-α (TNF-α) secretion of monocyte-derived dendritic cells or peripheral blood mononuclear cells. In some preferred embodiments, at least 50%, 55%, 60%, 65%, 70% or 75% of the cells contacted with a composition of the disclosure remain viable 40-56 hours (or about 48 hours) after contact.

[0089] In some embodiments, the method is suitable for stimulating an anti-tumor immune response. In other embodiments, the method is suitable for stimulating an anti-microbial immune response. In some embodiments, the anti-microbial response is an anti-bacterial immune response. In some embodiments, the anti-microbial response is an anti-fungal immune response. In some embodiments, the anti-microbial response is an anti-viral immune response. In some embodiments, the anti-microbial response is an anti-protozoan immune response. B. Treat or prevent disease

[0090] The present disclosure further provides methods for treating or preventing a disease in an individual, comprising administering to the individual a composition or formulation described herein in an amount sufficient to treat or prevent the disease in the individual. In some embodiments, the disease is cancer. In some embodiments, the disease is abnormal cell proliferation. In other embodiments, the disease is an infectious disease.

[0091] In one aspect, the method may include administering to a subject in need thereof a composition comprising an LPC compound and at least one additional lipid, wherein the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). On the other hand, the method relates to adoptive cell therapy and includes administering to a subject in need thereof a composition comprising dendritic cells (such as hyperactivated dendritic cells), an LPC compound, and additional lipids, wherein the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). In some embodiments, the composition further comprises a PRR agonist, an antigen, an adjuvant, or any combination thereof.

[0092] In some embodiments, the method relates to treating cancer in an individual or otherwise treating a mammalian subject with cancer. In some embodiments, the method comprises: a) preparing an immunogenic composition comprising a tumor cell lysate, a separated lysophosphatidylcholine (LPC) with a single acyl chain, at least one additional lipid and a toll-like receptor 7 / 8 (TLR7 / 8) agonist, wherein the tumor cell lysate is or has been prepared from a tumor sample obtained from a subject with cancer, the acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, and the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP); and b) administering an effective amount of the immunogenic composition to a subject. In some embodiments, cancer is a blood cancer, such as a lymphoma, leukemia, or myeloma. In other embodiments, cancer is a non-hematological cancer, such as a sarcoma, carcinoma, or melanoma. In some embodiments, cancer is malignant.

[0093] In some embodiments, the method involves inhibiting abnormal cell proliferation in an individual. "Abnormal cell proliferation" refers to the proliferation of a benign tumor or a malignant tumor. A malignant tumor can be a metastatic tumor.

[0094] In some embodiments, the method relates to treating or preventing an infectious disease in an individual. In some embodiments, the infectious disease is caused by a viral infection. In other embodiments, the infectious disease is caused by a bacterial infection. In a further embodiment, the infectious disease is caused by a fungal infection. In a still further embodiment, the infectious disease is caused by a protozoan infection. Of particular importance are infectious diseases caused by animal-derived pathogens that infect humans and other animals (such as mammals or birds). In some embodiments, animal-derived pathogens are transmitted to humans via intermediate species (carriers). List of implementation plans 1. A composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a TLR7 / 8 agonist, wherein The acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). 2. A composition according to embodiment 1, wherein the acyl chain is a C18-C22 acyl chain or a C21-C24 acyl chain. 3. The composition according to embodiment 1 or embodiment 2, further comprising an antigen. 4. The composition according to any one of embodiments 1-3, further comprising dendritic cells. 5. A composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and an antigen, wherein The acyl chain is a C21-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). 6. The composition according to embodiment 5, further comprising dendritic cells. 7. The composition according to embodiment 5 or embodiment 6, further comprising a TLR7 / 8 agonist. 8. A composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and dendritic cells, wherein The acyl chain is a C21-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). 9. The composition according to embodiment 8, further comprising a TLR7 / 8 agonist. 10. The composition of embodiment 8 or embodiment 9, further comprising an antigen. 11. The composition of any one of embodiments 1-10, wherein the acyl chain is a C22 acyl chain. 12. The composition of any one of embodiments 1-11, wherein the acyl chain is fully saturated. 13. A composition according to any one of embodiments 1-12, wherein the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)]. 14. A composition according to any one of embodiments 1-13, wherein the TLR7 / 8 agonist is a small molecule with a molecular weight of 900 Daltons or less. 15. The composition of embodiment 14, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound. 16. The composition of embodiment 15, wherein the TLR7 / 8 agonist comprises resiquimod (R848). 17. The composition of embodiment 14 or embodiment 15, wherein the TLR7 / 8 agonist does not inhibit NLR family pyrin domain-containing protein 3 (NLRP3). 18. A composition according to embodiment 13, wherein the LPC comprises LPC(22:0) and the TLR7 / 8 agonist comprises resiquimod (R848). 19. The composition of any one of embodiments 1-18, wherein the antigen is present in a biological sample obtained from an individual. 20. The composition of embodiment 19, wherein the biological sample comprises a biopsy tissue. 21. The composition of embodiment 19, wherein the biological sample comprises cells. 22. A composition according to embodiment 19, wherein the biological sample does not include cells. 23. The composition of embodiment 19, wherein the biological sample comprises pus from an abscess. 24. The composition of any one of embodiments 1-23, wherein the antigen comprises a protein antigen. 25. A composition according to embodiment 24, wherein the antigen comprises a tumor antigen. 26. A composition according to embodiment 25, wherein the tumor antigen comprises a synthetic or recombinant neoantigen. 27. A composition according to embodiment 26, wherein the tumor antigen comprises tumor cell lysate. 28. The composition of embodiment 24, wherein the antigen comprises a microbial antigen, and the microbial antigen comprises one or more of a viral antigen, a bacterial antigen, a protozoan antigen, and a fungal antigen. 29. The composition of embodiment 28, wherein the microbial antigens comprise purified or recombinant surface proteins. 30. The composition of embodiment 28, wherein the microbial antigen comprises an inactivated whole virus. 31. The composition of any one of embodiments 1-30, wherein the composition comprises liposomes. 32. A composition according to any one of embodiments 1-31, wherein the composition does not contain lipopolysaccharide (LPS) or monophosphoryl lipid A (MPLA). 33. The composition of any one of embodiments 1-32, wherein the composition does not comprise oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine (oxPAPC) or species of oxPAPC. 34. The composition of embodiment 33, wherein the composition does not contain 2-[[(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-hexadecanoyloxypropyloxy]-hydroxyphosphoryl]oxyethyl-trimethylazonium (HOdiA-PC), [(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-hexadecanoyloxypropyl]-hydroxyphosphoryl]oxyethyl-trimethylazonium (HOdiA-PC), [(2R)-2-[(E)-7-carboxy-5-oxohept-6-enoyl]oxy-3-hexadecanoyloxypropyl]-2-(trimethylazonium)ethylphosphoryl]oxyethyl-trimethylazonium ester (KOdiA-PC), 1-palmitoyl-2-(5-hydroxy-8-oxo-octenoyl)-sn-glycero-3-phosphatidylcholine (HOOA-PC), 2-[[(2R)-2-[(E)-5,8-dioxooct-6-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylammonium (KOOA-PC), [(2R)-3-hexadecanoyloxy-2-(5-oxopentanoyloxy)-sn-glycero-3-phosphatidylcholine (HOOA-PC), )propyl] 2-(trimethylazonium)ethyl phosphate (POVPC), [(2R)-2-(4-carboxybutyryloxy)-3-hexadecanoyloxypropyl] 2-(trimethylazonium)ethyl phosphate (PGPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[2-[(Z)-oct-2-enyl]-5-oxocyclopent-3-en-1-ylidene]methyl]oxiran-2-yl]butyryloxy]propyl] 2-(trimethylazonia)ethyl phosphate (PECPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[3-hydroxy-2-[(Z)-oct-2-enyl]-5-oxocyclopentylidene]methyl]oxiran-2-yl]butanoyloxy]propyl]2-(trimethylazonia)ethyl phosphate (PEIPC) and / or 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzePC). 35. The composition of any one of embodiments 1-34, further comprising an adjuvant, wherein the adjuvant comprises an aluminum salt adjuvant, a squalene-in-water emulsion, a saponin, or a combination thereof. 36. A pharmaceutical formulation comprising the composition according to any one of embodiments 1-35 and a pharmaceutically acceptable excipient. 37. A method for producing hyperactivated dendritic cells, the method comprising contacting the dendritic cells with an effective amount of a composition comprising isolated lysophosphatidylcholine (LPC) having a single C13-C22 acyl chain or a C13-C24 acyl chain, at least one additional lipid, and a TLR7 / 8 agonist to produce hyperactivated dendritic cells, wherein The hyperactivated dendritic cells secrete IL-1β without undergoing pyroptosis. The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). 38. The method of embodiment 37, wherein the dendritic cells are contacted ex vivo with the composition of any one of embodiments 1-35 or the formulation of embodiment 36. 39. The method of embodiment 37, wherein the dendritic cells are contacted with the formulation of embodiment 36 in vivo. 40. A pharmaceutical formulation comprising at least 10 3 , 10 4 , 10 5 or 10 6 A hyperactivated dendritic cell produced by the method according to embodiment 38 and a pharmaceutically acceptable excipient. 41. A method of stimulating an immune response to an antigen, the method comprising administering to an individual in need thereof an effective amount of the formulation according to embodiment 36 to stimulate the immune response to the antigen. 42. A method of treating cancer, the method comprising administering to an individual in need thereof an effective amount of the formulation according to embodiment 36 to treat the cancer. 43. A method of inhibiting abnormal cell proliferation, the method comprising administering to an individual in need thereof an effective amount of the formulation according to embodiment 36 to inhibit abnormal cell proliferation. 44. A method of treating an infectious disease, the method comprising administering to an individual in need thereof an effective amount of the formulation according to embodiment 36 to treat the infectious disease. 45. Use of the formulation of embodiment 36 for inducing an immune response against an antigen in an individual in need thereof. 46. ​​Use of the formulation of embodiment 36 for inducing an anti-tumor immune response in an individual in need thereof, wherein the individual bears or has had a tumor. 47. Use of the formulation of embodiment 36 for inducing an anti-microbial immune response in an individual in need thereof, wherein the individual is infected with the microorganism or has not been exposed to the microorganism. 48. The composition, formulation, method or use of any one of embodiments 19-47, wherein the individual is a mammalian subject. 49. The composition, formulation, method or use of any one of embodiments 19-47, wherein the individual is a human subject. 50. A method of preparing an immunogenic composition, the method comprising: a) obtaining a suspension rich in tumor cells from the tumor; b) lysing cells from the tumor cell-enriched suspension to obtain a tumor cell lysate; and c) contacting the tumor cell lysate with a composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a toll-like receptor 7 / 8 (TLR7 / 8) agonist to obtain the immunogenic composition, wherein The acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). 51. The method of embodiment 50, wherein step a) comprises depleting leukocytes from the tumor cell-enriched suspension, optionally wherein the leukocytes are depleted by negative selection using an anti-CD45 antibody. 52. The method of embodiment 50 or embodiment 51, wherein in step b) the cells are lysed by one or more freeze-thaw cycles. 53. A method according to any one of embodiments 50-52, wherein the acyl chain is a fully saturated C18-C22 acyl chain or a fully saturated C18-C24 acyl chain. 54. A method according to embodiment 53, wherein the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)]. 55. A method according to any one of embodiments 50-54, wherein the TLR7 / 8 agonist is a small molecule with a molecular weight of 900 Daltons or less. 56. A method according to embodiment 55, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound. 57. The method of embodiment 56, wherein the TLR7 / 8 agonist comprises resiquimod (R848). 58. The method of embodiment 55 or embodiment 56, wherein the TLR7 / 8 agonist does not inhibit NLR family pyrin domain-containing protein 3 (NLRP3). 59. A method according to embodiment 54, wherein the LPC includes LPC (22:0) and the TLR7 / 8 agonist includes resiquimod (R848). 60. The method according to any one of embodiments 50-59, further comprising obtaining a sample from the tumor from a mammalian subject suffering from cancer before step a), and preparing the cell suspension from the sample. 61. An immunogenic composition prepared by the method of any one of embodiments 50-60. 62. A method for eliciting an anti-cancer immune response, the method comprising: An effective amount of the immunogenic composition of Embodiment 61 is administered to a mammalian subject having cancer. 63. A method according to embodiment 62, wherein the anti-cancer immune response comprises a cellular immune response. 64. A method according to embodiment 63, wherein the anti-cancer immune response includes cancer antigen-induced IL-1β secretion and / or CD8+T lymphocyte activation. 65. The method of any one of embodiments 62-64, wherein the cancer is a non-hematological cancer. 66. The method of embodiment 65, wherein the non-hematological cancer is carcinoma, sarcoma, or melanoma. 67. The method of any one of embodiments 62-64, wherein the cancer is lymphoma. 68. A method of treating cancer, the method comprising: a) preparing an immunogenic composition comprising a tumor cell lysate, isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a toll-like receptor 7 / 8 (TLR7 / 8) agonist, wherein The tumor cell lysate is or has been prepared from a tumor sample obtained from a mammalian subject suffering from cancer, The acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP); and b) administering an effective amount of the immunogenic composition to the subject. 69. The method of any one of embodiments 62-68, wherein the acyl chain is a fully saturated C18-C22 acyl chain or a fully saturated C18-C24 acyl chain. 70. A method according to embodiment 68, wherein the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)]. 71. A method according to any one of embodiments 62-70, wherein the TLR7 / 8 agonist is a small molecule with a molecular weight of 900 Daltons or less. 72. A method according to embodiment 71, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound. 73. A method according to embodiment 72, wherein the TLR7 / 8 agonist comprises resiquimod (R848). 74. A method according to embodiment 70, wherein the LPC comprises 22:0LPC and the TLR7 / 8 agonist comprises resiquimod (R848). 75. The method of any one of claims 68-74, further comprising administering to the subject an effective amount of an additional therapeutic agent. 76. A method according to embodiment 75, wherein the additional therapeutic agent includes one or more of the group consisting of an immune checkpoint inhibitor, an anti-tumor agent, and radiation therapy. 77. A composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid, and a pathogen recognition receptor (PRR) agonist, wherein the acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). 78. The composition of embodiment 77, wherein the PRR agonist is an agonist of a toll-like receptor (TLR), a NOD-like receptor (NLR), a RIG-I-like receptor (RLR), or a C-type lectin receptor (CLR). 79. A composition according to embodiment 77, wherein the PRR agonist is an agonist of cytoplasmic DNA sensor (CDS) or stimulator of IFN genes (STING). 80. A composition according to embodiment 77, wherein the PRR agonist includes one or more of R848, TL8-506, LPS, Pam2CSK4 and ODN 2336. 81. The composition of any one of embodiments 77-80, further comprising an antigen. 82. The composition of any one of embodiments 77-81, further comprising dendritic cells. 83. A pharmaceutical formulation comprising a composition according to any one of embodiments 77-82 and a pharmaceutically acceptable excipient. 84. A pharmaceutical formulation comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid, and a pharmaceutically acceptable excipient, wherein the acyl chain is a C21-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). 85. The pharmaceutical formulation of embodiment 83 or embodiment 84, wherein the acyl chain is a fully saturated C22 acyl chain. 86. The pharmaceutical formulation of embodiment 85, wherein the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)]. 87. A composition for superactivating human dendritic cells, the composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a pathogen recognition receptor (PRR) agonist, wherein The acyl chain is a C22 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, the LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP), and the composition is effective for achieving a higher level of dendritic cell hyperactivation than a comparative composition comprising PGPC in place of the LPC. 88. A composition according to embodiment 87, wherein the higher level of dendritic cell hyperactivation comprises inducing IL-1β secretion from the human dendritic cells in vitro at a level that is at least 2, 3 or 4 times higher when contacted with the composition comprising the LPC and the PRR agonist than when contacted with the comparative composition comprising the PGPC and the PRR agonist, wherein the PRR agonist is LPS. 89. A composition according to embodiment 88, wherein the concentration of LPC and the concentration of PGPC are the same concentration ranging from about 10 μM to about 80 μM, and the LPS is present in both the composition and the comparative composition at a concentration of 1 μg / ml. 90. A composition according to embodiment 88, wherein the higher level of dendritic cell hyperactivation includes the following lipid activity index for IL-1β secretion from the human dendritic cells of the composition comprising the LPC and the PRR agonist, which is at least 4, 5 or 6 times higher in activity units than the lipid activity index of the comparative composition comprising the PGPC and the PRR agonist. 91. The composition, formulation, method or use of any one of embodiments 19-47, wherein the individual is a canine subject. 92. The composition, formulation, method or use of any one of embodiments 60-90, wherein the mammalian subject is a human patient. 93. The composition, formulation, method or use of any one of embodiments 60-90, wherein the mammalian subject is a non-human patient. 94. The composition, formulation, method or use of any one of embodiments 60-90, wherein the mammalian subject is a canine patient. 95. The composition, formulation, method or use of any one of embodiments 1-90 or 92, wherein the dendritic cells are human dendritic cells. 96. The composition, formulation, method or use of any one of embodiments 1-91 or 94, wherein the dendritic cells are canine dendritic cells. 97. The composition, formulation, method or use of embodiment 95 or embodiment 96, wherein the dendritic cells are present in a composition comprising peripheral blood mononuclear cells (PBMCs). 98. The composition, formulation, method or use of any one of embodiments 37-49 or embodiment 91, wherein the hyperactivated dendritic cells secrete one or both of IFNγ and TNFα. 99. The composition, formulation, method or use of any one of embodiments 1-98, wherein the at least one additional lipid comprises one or both of an additional phospholipid and a structural lipid, optionally wherein the additional phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and the structural lipid comprises cholesterol. 100. The composition, formulation, method or use of embodiment 99, wherein the at least one additional lipid comprises a PEGylated lipid, optionally wherein the PEGylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoylglycerol [DMG]. 101. The composition, formulation, method or use of embodiment 99 or embodiment 100, wherein the at least one additional lipid comprises an ionizable lipid, optionally wherein the ionizable lipid comprises 4-(dimethylamino)-butyric acid, (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecadien-1-yl ester (DLin-MC3-DMA) or an analog or derivative thereof. 102. A composition comprising lipid nanoparticles (LNPs), wherein the LNPs comprise a first phospholipid and at least one lipid, wherein the at least one lipid is selected from an ionizable lipid, a second phospholipid, a pegylated lipid, a structured lipid, and a mixture thereof, wherein the first phospholipid comprises a lysophosphatidylcholine (LPC) having a single acyl chain, and the acyl chain is a C13-C24 acyl chain. 103. A composition comprising lipid nanoparticles (LNPs), wherein the LNPs comprise a first phospholipid, an ionizable lipid, a second phospholipid, a pegylated lipid, and a structural lipid, wherein the first phospholipid comprises a lysophosphatidylcholine (LPC) having a single acyl chain, and the acyl chain is a C13-C24 acyl chain. 104. A composition according to any one of embodiments 1-103, wherein the ionizable lipid comprises: i) 8-[(2-hydroxyethyl)[6-oxo-6-(undecanyloxy)hexyl]amino]octanoic acid, 1-octylnonyl ester (SM-102) or an analog or derivative thereof; and / or 6-((2-hexyldecanoyl)oxy)-N-(6-((2-hexyldecanoyl)oxy)hexyl)-N-(4-hydroxybutyl)hexane-1-ammonium (ALC-0315) or an analog or derivative thereof; or ii) (6Z,9Z,28Z,31Z)-triacontane-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butyrate (DLin-MC3-DMA) or an analog or derivative thereof. 105. A composition according to any of embodiments 1-104, wherein the PEGylated lipid is selected from PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol and combinations thereof. 106. A composition according to any one of embodiments 1-104, wherein the PEGylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoylglycerol [DMG]. 107. A composition according to any one of embodiments 1-106, wherein the structured lipid is selected from: cholesterol, coprostanol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, α-tocopherol and combinations thereof. 108. A composition according to any one of embodiments 1-106, wherein the structured lipid comprises cholesterol. 109. A composition according to any of embodiments 1-108, wherein the additional phospholipid or the second phospholipid comprises a hydrophilic head portion, and the hydrophilic head portion is selected from phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine and sphingomyelin. 110. A composition according to embodiments 1-108, wherein the additional phospholipid or the second phospholipid comprises one or more fatty acid tail moieties, and the one or more fatty acid tail moieties are selected from lauric acid, myristic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, erucic acid, arachidic acid, arachidonic acid, phytanic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid and docosahexaenoic acid. 111. The composition of any one of embodiments 1-108, wherein the additional phospholipid or the second phospholipid is selected from: 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-Dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine, 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine, 1,2-Dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-Diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine, 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-Diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dioleoyl-sn-glycero-3-phospho-racemic-(1-glycerol) sodium salt (DOPG), sphingomyelin and Its combination. 112. The composition of any one of embodiments 1-108, wherein the additional phospholipid or the second phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). 113. A composition according to any one of embodiments 1-112, wherein the at least one additional lipid comprises: i) a cationic lipid, and comprises or further comprises ii) a neutral or anionic lipid. 114. The composition of embodiment 113, wherein the cationic lipid comprises one or both of: i) 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) or its analogs or derivatives; and ii) 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) or an analogue or derivative thereof. 115. The composition of embodiment 113 or embodiment 114, wherein the neutral or anionic lipid comprises: i) 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) or an analogue or derivative thereof; and / or ii) cholesterol or its analogs or derivatives; and / or iii) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or an analogue or derivative thereof. 116. A composition according to any one of embodiments 102-115, wherein the acyl chain of the LPC is a C21-C24 acyl chain. 117. A composition according to any one of embodiments 102-115, wherein the acyl chain of the LPC is a C22 acyl chain. 118. A composition according to any one of embodiments 102-117, wherein the composition further comprises a TLR7 / 8 agonist. 119. A composition according to embodiment 118, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound. 120. A composition according to embodiment 119, wherein the TLR7 / 8 agonist comprises resiquimod (R848). 121. A composition according to embodiment 119, wherein the LPC comprises LPC(22:0) and the TLR7 / 8 agonist comprises resiquimod (R848). 122. The composition of any one of embodiments 102-121, wherein the composition further comprises an antigen. 123. The composition of embodiment 122, wherein the antigen is a tumor antigen or a neoantigen. 124. The composition of embodiment 122, wherein the antigen is a microbial antigen, optionally wherein the microbial antigen is a viral antigen, a bacterial antigen, a protozoan antigen, or a fungal antigen. 125. The composition, formulation, method or use of any one of embodiments 1-124, wherein the composition does not comprise isolated mRNA. 126. The composition, formulation, method or use of any one of embodiments 1-125, wherein the LNP has an effective diameter of less than about 500 nanometers, optionally about 5 to about 500 nanometers, optionally about 10 to about 400 nanometers, optionally about 20 to about 300 nanometers, or optionally about 25 to about 250 nanometers. 127. The composition, formulation, method or use of embodiment 126, wherein the LNP has an effective diameter of less than about 250 nanometers. 128. The composition, formulation, method or use of embodiment 127, wherein the LNP has an effective diameter of less than about 125 nanometers. 129. The composition, formulation, method or use of embodiment 128, wherein the LNP has an effective diameter of about 10 to about 110 nanometers. 130. The composition, formulation, method or use of any one of embodiments 1-129, wherein the composition does not comprise a surfactant. Example

[0095] Abbreviations: CDS (cytoplasmic DNA sensor); CLR (C-type lectin receptor); DAMP (damage-associated molecular pattern); DC (dendritic cell); dLN (draining lymph node); DLS (dynamic light scattering); DMG-PEG-2000 (polyethylene glycol [PEG] 2000 dimyristoylglycerol [DMG]); DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine); ELSD (evaporative light scattering detector); FLT3L (Fms-related tyrosine kinase 3 ligand); HOdiA-PC (1-palmitoyl-2-(5-hydroxy-8-oxo-6-octenedioyl)-1-hydroxy ... 1-(palmitoyl)-2-(5-hydroxy-8-oxooct-6-enoyl)-sn-glycero-3-phosphocholine); HOOA-PC (1-palmitoyl-2-(5-hydroxy-8-oxooct-6-enoyl)-sn-glycero-3-phosphocholine); IFNγ (interferon-γ); IL-1b / IL1-β / IL-1β (interleukin-1β); KOdiA-PC (1-(palmitoyl)-2-(5-keto-6-octen-diacyl)phosphatidylcholine); KOOA-PC (1-palmitoyl-(5-keto-8-oxo-6-octenoyl)-sn-glycero-3-phosphocholine); LNP (lipid nanoparticle); LPC / Lyso PC (lysophosphatidylcholine); Lyso PC(22:0) (1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine); LPS (lipopolysaccharide); MC3 ((6Z,9Z,28Z,31Z)-triacontriacontane-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butyrate, also known as DLin-MC3-DMA); moDC (monocyte-derived dendritic cell); MPLA (monophosphoryl lipid A); NLR (NOD-like receptor); oxPAPC (oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine) ; PAMP (pathogen-associated molecular pattern); PBMC (peripheral blood mononuclear cell); PGPC (1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine); POVPC (1-palmitoyl-2-(5'-oxo-pentanoyl)-sn-glycero-3-phosphocholine); PRR (pathogen recognition receptor); RLR (RIG-I-like receptor); R848 (resiquimod); SC (subcutaneous); STING (stimulator of IFN genes); TNFα (tumor necrosis factor-α); and TLR (toll-like receptor).

[0096] Although for the purpose of clarity and understanding, the disclosure has been described in detail by way of illustration and example, it will be clear to those skilled in the art that certain changes and modifications may be implemented. Therefore, the following examples should not be construed as limiting the scope of the disclosure, which is defined by the appended claims. Example 1: Combination of Lysophosphatidylcholine (LPC) with a Single Acyl Chain and TLR7 / 8 Agonist Superactivates Mammalian Peripheral Blood Mononuclear Cells

[0097] This example describes the hyperactivation of canine and human peripheral blood mononuclear cells (PBMCs) using a combination of lipid DAMPs and small molecule PAMPs. Materials and methods

[0098] PBMCs were separated from whole blood. PBMCs were separated from whole blood using density gradient centrifugation with Ficoll-Paque PLUS (Cytivia). Whole blood was diluted with PBS at 1:1, layered on the top of Ficoll-Paque PLUS, and centrifuged at room temperature for 30 minutes at 1000 x g. PBMCs were collected, washed twice in PBS, and incubated with Ack lysis buffer (Lonza) to remove any residual erythrocytes.

[0099] Cell culture and stimulation. Immediately after isolation, PBMCs were plated in RPMI medium (R10 medium) containing 10% FBS, 50 units / mL penicillin, 50 mg / mL streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 50 mM β-mercaptoethanol. Cells were plated at 1 x 10 5 (canine cells) or 1x 10 6 (Human cells) were plated in 96-well flat-bottom tissue culture plates. Lyophilized Vaccigrade R848 (Invivogen) was reconstituted and diluted according to the manufacturer's recommendations and added to the cells at a final concentration of 1 μg / mL. Next, 22:0LYSO PC was added to the cells at a final concentration of 82.5 μM. Additional innate agonists were diluted in R10 medium according to the manufacturer's recommendations and added to the cells as follows: human GM-CSF (Peprotech) was added at a final concentration of 10 ng / mL; 2'3'cGAMP (Invivogen) was added at a final concentration of 15 μg / mL; LPS serotype O55:B5 (Enzo Life Sciences) was added at a final concentration of 1 μg / mL; aluminum adjuvant hydroxide (Invivogen) was added at a final concentration of 30 μg / mL. The cells were incubated at 37°C, 5% CO2 for two days. The cell cultures were then used for endpoint analysis.

[0100] Endpoint analysis. After culturing PBMC with PAMPs and DAMPs for two days, supernatants and cell samples were collected for analysis. Cells in the culture were pelleted by centrifugation at 400 x g for 5 minutes. Half of the culture volume in the collection wells was used for ELISA or Lumit TMCytokine quantification was performed by bioluminescence assay, while the remaining medium and cells were used to quantify cell viability by assessing metabolic activity.

[0101] Quantification of cytokine secretion. IL-1β secretion by human PBMCs was assessed using one of the following kits: ELISA MAXDeluxe Set Human IL-1β Kit (Biolegend), Invitrogen Human IL-1β Kit, or Lumit TM Human IL-1β immunoassay (Promega). IFNγ secretion from human PBMCs was assessed using ELISA MAX Deluxe Set Human IFNγ (Biolegend), and TNFα secretion from human PBMCs was assessed using the Human TNFα Uncoated ELISA Kit (Invitrogen). ELISAs were performed according to the manufacturer's instructions with the following modifications: i) the total sample + buffer volume for incubation was reduced from 100 μL to 50 μL; ii) the top standard was prepared at 500 pg / mL and diluted two-fold to 7.8 pg / mL; and iii) samples were incubated overnight at 4°C on an orbital shaker. Lumit TM Assay. IL-1β secretion by canine PBMCs was assessed using the Canine IL-1β / IL-1F2 DuoSet ELISA (R&D) according to the manufacturer's instructions with the following modifications: i) the total sample + buffer volume for incubation was reduced from 100 μL to 50 μL; ii) overnight incubation of samples was done at 4°C on an orbital shaker. For all ELISAs, absorbance was measured at 450 nm with calibration at 570 nm using a Spectramax M5e plate reader (Molecular Devices). For Lumit TM For determination, luminescence at all wavelengths was measured using a Spectramax M5e plate reader (Molecular Devices) with an integration time of 500 ms. To determine the cytokine concentration in the supernatant, sample concentrations were interpolated using a standard curve via 4PL analysis on GraphPad Prism 9 (GraphPad Software). The interpolated results for the samples were then adjusted for any dilution of the supernatant.

[0102] Quantification of cell viability.Cell viability was assessed by quantifying the presence of ATP as an indicator of metabolically active cells using CellTiter-Glo luminescent cell viability assay (Promega).Metabolic activity was assessed following the manufacturer's instructions.CellTiter-Glo reagent was mixed with cell pellets and fresh culture medium and then transferred to a white opaque 96-well plate.Luminescence at all wavelengths was measured on a Spectramax M5e plate reader (Molecular Devices) using an integration time of 500ms.The viability percentage relative to the control condition of the PBMCs treated with R848 was calculated.

[0103] Statistical analysis.For each condition, the cell plating from each donor was tested in triplicate.For cytokine quantification, triplicate replicates were used for interpolation, and data were plotted as total concentration (pg / mL) or the change multiple of each donor relative to the control condition of only R848.For vigor quantification, triplicates were repeated to average each donor, and average was used as a donor measurement.Multiple donors were tested, and each data point on the bar graph represents the value of the donor.In order to test the difference of test conditions, the test results were compared with the control condition of only R848. P values ​​were calculated using mixed effects one-way ANOVA, and multiple comparisons were corrected using Dunnett's test. Results - Hyperactivated canine PBMCs treated with 22:0LYSO PC and R848

[0104] The combination of 22:0LYSO PC (DAMP) and TLR7 / 8 agonist R848 (PAMP) was previously found to have potent superstimulatory activity in human moDC. To assess whether this superstimulatory activity translates to other clinically relevant species, the ability of 22:0LYSO PC+R848 to superactivate PBMCs isolated from canine whole blood was evaluated. For each data set, PBMCs from multiple donors were used instead of moDCs due to the lack of canine-specific reagents that can be used to induce true canine moDCs. Briefly, PBMCs were isolated from whole blood using density gradient centrifugation and then cultured for two days with the superactivating stimuli of interest.

[0105] After two days of culture, hyperactivation was assessed by quantifying IL-1β in the cell culture supernatant and measuring cell viability. Canine PBMCs secreted comparable or higher levels of IL-1β when treated with 22:0LYSO PC and R848 together compared to each of the other stimuli tested, both as concentration per mL and as fold change for each donor relative to R848 alone ( Figure 1A-1B). Consistent with previous studies showing that monocytes, which constitute 5%-10% of PBMCs, canine PBMCs secreted elevated levels of IL-1β in the presence of R848 alone compared to untreated cells. As expected, the pyroptotic combination of LPS+aluminum adjuvant elicited high levels of IL-1β. Notably, while PGPC+R848 elicited similar levels of IL-1β compared to R848 alone, neither GM-CSF nor 2'3'cGAMP induced significant IL-1β secretion from canine PBMCs compared to untreated cells.

[0106] Although IL-1β could be detected in the cell culture supernatant one day after superactivation of canine PBMCs, cell viability was assessed two days after superactivation to ensure sustained viability after IL-1β secretion. 22:0 LYSO + R848 did not significantly reduce relative cell viability ( Figure 1C ). Interestingly, the combination of PGPC and R848 demonstrated some toxicity to canine PBMCs, although it was not observed to be toxic to human moDCs or human PBMCs. However, interpreting observations obtained from testing mixed cell populations is challenging, as the viability of the specific cell population of interest (in this case, monocytes) cannot be determined from the results obtained with the mixture. Together, these data demonstrate that 22:0LYSO+R848 elicits high levels of IL-1β secretion from canine PBMCs, suggesting hyperactivation. Results - Treatment of hyperactivated human PBMCs with 22:0LYSO PC and R848

[0107] Superactivation experiments were also performed with PBMCs isolated from whole blood obtained from human donors. Briefly, PBMCs were isolated from whole blood from multiple human donors by density gradient centrifugation and cultured for two days with the superactivating stimuli of interest.

[0108] Like human moDCs and canine PBMCs, human PBMCs secreted IL-1β at levels higher or comparable to all other stimuli tested ( Figure 2A-2B ). Similar to canine PBMCs, human PBMCs secreted IL-1β in response to R848 alone due to monocyte activation, and this secretion was increased by the addition of 22:0LYSO PC. As expected, the pyroptosis combination of LPS+aluminum adjuvant elicited high levels of IL-1β. Consistent with the observations in canine PBMCs, PGPC+R848 did not induce significantly higher levels of IL-1β than R848 alone. GM-CSF did not induce human PBMCs to secrete levels of IL-1β significantly above the background level produced by untreated cells.

[0109] The viability of human PBMCs was also assessed two days after superactivation to ensure the sustained viability of human PBMCs after IL-1β secretion. No significant decrease in the viability of human PBMCs was observed after treatment with any of the stimuli ( Figure 2C ). However, interpreting the observations obtained from testing mixed cell populations is challenging because the viability of a specific cell population of interest (in this case, monocytes) cannot be determined from the results obtained with the mixture. Together, these data demonstrate that both human and canine PBMCs are superactivated by 22:0LYSO PC+R848. Interestingly, canine PBMCs are superactivated to a greater extent by 22:0LYSO PC+R848 than by PGPC+R848.

[0110] Because activated human PBMCs can secrete other cytokines in addition to IL-1β, secretion of proinflammatory cytokines IFNγ and TNFα was measured in cell culture supernatants two days after superactivation. The combination of 22:0LYSO PC + R848 induced the highest fold change per donor relative to R848 alone in both IFNγ secretion and TNFα secretion compared to all other stimuli tested ( Figure 3A-3B ). It is noteworthy that although LPS+Al adjuvant induced high levels of IL-1β secretion from human PBMCs ( Figure 3B ), but this combination of stimuli did not induce a fold increase in IFNγ or TNFα secretion. In addition, neither GM-CSF nor 2'3' cGAMP triggered a substantial fold change in IFNγ secretion relative to R848 alone. These data suggest that the combination of 22:0LYSO PC+R848 is superior in inducing secretion of the proinflammatory cytokines IFNγ and TNFα from human PBMCs. Example 2: Preparation of lipid nanoparticles containing lysophosphatidylcholine (LPC)

[0111] This example describes the preparation of lipid nanoparticles (LNPs) loaded with hyperactivated lipids (eg, 22:0 LYSO PC) in a microfluidic process. Materials and methods

[0112] use Ignite TM LNPs were synthesized using a microfluidic instrument (Precision Nanosystems, Vancouver, British Columbia, Canada). TMThe kit (Precision Nanosystems, Vancouver, British Columbia, Canada) of ionizable lipid mixture produces LNP. The kit without mRNA is used to construct an empty LNP vehicle, and the LNP loaded with super activator is generated by adding 22:0Lyso PC to a molar ratio of 10% of the total LNP content. LNPs are also produced using separate components (without the kit) to determine whether the 22:0Lyso PC loading in the LNP can be intentionally changed. LNPs are prepared by combining the following components with or without 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine: (CAS Reg. No. 125146-65-8, referred to herein as "22:0 Lyso PC") (Avanti): (10Z,13Z)-1-(9Z,12Z)-9,12-octadecadien-1-yl-10,13-nonadecadien-1-yl ester (CAS Reg. No. 1224606-06-7, referred to herein as "DLin-MC3-DMA" or "MC3") (Cayman Chemical); 1,2-Distearoyl-sn-glycero-3-phosphocholine (CAS Registry Number 816-94-4, referred to herein as "DSPC") (Avanti); Cholesterol (Sigman); and 1,2-Dimyristoyl-racemic-glycerol-3-methoxypolyethylene glycol-2000 (CAS Reg. No. 160743-62-4, referred to herein as "DMG-PEG2000") (Avanti). The lipids were first dissolved in ethanol and then combined according to the molar concentration percentages shown in Table 2-1. The lipids in ethanol were combined with PBS at pH 7.4 at a volume ratio of 1:3. Ignite TM The microfluidic instrument was programmed with a flow rate of 12 mL / min, a start waste of 0.35 mL, and an end waste of 0.05 mL. The LNPs were washed in PBS, pH 7.4 to remove residual ethanol and then concentrated using an Amicon 10K MWCO centrifugal filter by spinning at 2000 x g for 30 minutes. Table 2-1. LNP formulations^ ^Molar concentration percentages of components of different LNP formulations. LNP 2 and LNP 3 formulations share the same vehicle (LNP Vehicle 2).

[0113] HPLC was used to evaluate the loading of 22:0Lyso PC in LNPs. The LNPs in PBS were frozen at -80°C and then lyophilized and stored at -20°C until they could be quantified. The LNPs were reconstituted in ethanol and then mixed with water to dissolve the PBS. A seven-point standard curve for 22:0Lyso PC was prepared in ethanol and water and PBS added to match the sample preparation. Standards and samples were filtered through a 0.45 μm filter before running on the HPLC. HPLC quantification was performed using an Agilent 1260 Infinity II HPLC equipped with a 1260 Infinity II evaporative light scattering detector (ELSD). A Luna 5 μm NH2 column with a column temperature of 30°C was used. Samples were tested on a 150X 4.6mm LC column (Phenomenex, Torrance, California). Two eluents were used: A, 100% water; and B, 100% acetonitrile. The column was loaded with an initial mobile phase consisting of 5% / 95% A / B, with a gradient reaching 24% / 76% A / B after 2.5 minutes. A shallower gradient was used from 2.5 to 6 minutes, with A / B slowly reaching 25% / 75% over this time frame. A 3-minute post-time was used to return the gradient to the starting conditions before the next sample was run. The flow rate was set to 1 mL / min, and the injection volume for samples and standards was 5 μL. The ELSD used an evaporator temperature of 80°C, a nebulizer temperature of 30°C, and a nitrogen flow rate of 0.9 standard liters / minute. Agilent CDS2.6 software was used for HPLC instrument control, data acquisition, and processing.

[0114] The size of LNPs was assessed using dynamic light scattering (DLS) on a NanoBrook Omni particle size and zeta potential analyzer (Brookhaven Instruments Corp., Hotsville, New York). Four measurements were performed for 120 seconds each for each sample, with the first measurement for each sample excluded from downstream analysis because of the time required for sample equilibration. The data points on the size estimation graph represent single replicate measurements from two preparations of LNPs. result

[0115] Incorporation of 22:0Lyso PC into LNPs was investigated to test the effect of 22:0Lyso PC on the physical characteristics and bioactivity of the LNPs.Both the loading level and the amount of loaded LNPs are considered key variables affecting the 22:0Lyso PC payload delivered to cells.

[0116] Using GenVoy-ILM TMIonizable lipid mixture (Precision Nanosystems, Vancouver, British Columbia, Canada) was used to generate LNPs with or without 10% 22:0Lyso PC (based on molar ratio). Additional LNPs were generated by combining the following components with or without 22:0LysoPC:MC3, DPSC, cholesterol, and DMG-PEG2000. All LNPs were prepared by using Ignite TM The LNPs were generated using a microfluidic instrument (Precision Nanosystems, Vancouver, British Columbia, Canada). The LNPs were subsequently purified using spin filtration to remove ethanol and unincorporated materials.

[0117] Dynamic light scattering (DLS) was used to determine the size of the LNP formulations to determine their average effective diameter. Two LNP batches of each formulation were prepared, and three size estimation measurements were performed for each batch. Depending on the addition of formulation and 22:0LysoPC, the diameter range of the LNPs was 50 to 200 nm ( Figure 4 The addition of 22:0Lyso PC did not appear to have a significant effect on the effective diameter of the LNPs in any of the formulations tested.

[0118] Four kinds of LNP formulations tested start with different 22:0LPC molar ratio inputs. In order to determine whether adjusting the input ratio affects the loading level of 22:0Lyso PC in LNP, the amount of 22:0Lyso PC present in LNP is assessed using HPLC. The LNP preparations are freeze-dried and then dissolved in a mixture of ethanol and water for quantification. The samples are compared with the standard curve of 22:0Lyso PC prepared using the same dissolution conditions. 22:0Lyso PC is successfully detected in the preparations including it in the initial input, and is not detected in its corresponding empty vehicle control ( Figure 5A-5C ). Assuming that the efficiency of 22:0Lyso PC incorporation into LNPs is 100%, the theoretical value of lipid incorporation was calculated. The actual amount of 22:0Lyso PC measured by HPLC was within 75% of the theoretical value ( Figure 5D ). As the input of 22:0Lyso PC increased, the measured 22:0Lyso PC loading into the LNPs also increased. This suggests that the 22:0Lyso PC loading in the LNPs can be adjusted based on the amount of 22:0Lyso PC required for a specific application. Example 3: Superactivation of human dendritic cells with a combination of TLR7 / 8 agonists and lipid nanoparticles containing lysophosphatidylcholine (LPC)

[0119] This example describes the superactivation of human monocyte-derived dendritic cells (moDCs) using a combination of TLR7 / 8 agonists and LNPs loaded with superactivating lipids (eg, 22:0 LYSO PC). Materials and methods

[0120] Human monocytes were isolated from Leukopaks purchased from Miltenyi Inc. (San Jose, California) using the StraightFrom Leukopak CD14 microbead kit according to the manufacturer's instructions. The monocytes were then aliquoted and frozen in fetal bovine serum containing 10% dimethyl sulfoxide. For the study of monocyte-derived dendritic cell (moDC) cultures, monocytes were thawed and cultured in RPMI medium (R10 medium) containing 10% FBS, 50 units / mL penicillin, 50mg / mL streptomycin, 2mML-glutamine, 1mM sodium pyruvate, 50mMβ-mercaptoethanol, 10mM HEPES and Gibco MEM non-essential amino acids. In order to differentiate monocytes into moDC, recombinant human GM-CSF (50ng / mL) and IL-4 (25ng / mL) were added to the R10 medium. The cells were cultured with GM-CSF and IL-4 for 6 days and on day 3 the cells were fed with R10 medium containing GM-CSF and IL-4.

[0121] Six days after differentiation, moDCs were collected and counted. Cells were plated at 1 x 10 5 Cells / well were plated in 96-well flat-bottom plates. Cells were treated with or without 1 μg / mL R848 (final) and with or without super-activated lipids (or vehicle control). Two assays were used to measure the superactivity induced by LNP. The CellTiter-Glo assay (Promega) detects ATP as a measure of cell viability. The IL-1βLumit assay (Promega) measures the IL-1β cytokine present in the moDC cell culture supernatant. The experimental conditions were tested in triplicate, and the average results from one donor were plotted. The data represent the results of six human donor samples tested in two experiments. result

[0122] Superactive moDCs retain cell viability while producing IL-1β, an important cytokine in the generation and reactivation of long-lived memory T cells. The ability of LNPs prepared as described in Example 2 to superactivate human moDCs was tested. For comparison, 22:0Lyso PC was also simply resuspended in PBS medium, which made it a large, insoluble, flake material. When cell viability was measured using the ATP quantification assay, most experimental conditions had negligible effects on cell viability ( Fig. 6AThe most notable exception was the treatment of moDCs with LNPs prepared with GenVoy-ILM, where the mean viability was less than 75% (relative to R848 treatment alone). GenVoy-ILM LNPs induced IL-1β production regardless of whether 22:0Lyso PC was included in the formulation ( Figure 6B ). Given the reduced cell viability, it is speculated that GenVoy-ILM LNPs have caused cell death, and thus IL-1β release may not be the result of moDC hyperactivation.

[0123] When cells were dosed with 22:0Lyso PC directly resuspended in PBS, IL-1β was produced at the expense of cell viability ( Fig. 6A ). In addition, 22:0Lyso PC in PBS in large flake form resulted in inconsistent dosing of moDCs, and thus replicates were variable when using donor-derived moDCs. In contrast, the LNP formulations had a more consistent IL-1β response. 22:0Lyso PC LNPs induced IL-1β secretion above background measurements of their corresponding empty LNP vehicle controls ( Figure 6B ). Interestingly, despite dosing at 82.5 μM of 22:0Lyso PC in different formulations, cells treated with fewer LNPs loaded with more 22:0Lyso PC per LNP produced increased amounts of IL-1β. Formulations containing 10% 22:0Lyso PC (GenVoy and LNP1) did not have increased immunogenicity compared to their vehicle controls. In contrast, formulations containing 25% or 40% 22:0Lyso PC did induce higher levels of IL-1β secretion compared to their vehicle controls, with LNPs containing 40% 22:0Lyso PC inducing the highest levels of IL-1β secretion. These data suggest that a given payload of 22:0Lyso PC per LNP is an important contributor to moDC superactivation. An equivalent amount of 22:0Lyso PC spread over more LNPs is less efficient in superactivation.

[0124] In summary, the data prove that 22:0Lyso PC can be incorporated into LNP. It is expected that this new formulation method is clinically meaningful because it allows fine-tuning the amount of 22:0Lyso PC incorporated into the particles, which can have a significant impact on the efficiency of super activation. Despite the super activation, the 22:0Lyso PC in PBS cannot provide the same level of adjustability. In addition, another problem of preparing 22:0Lyso PC in PBS is the formation of very large visible particles that are unevenly distributed in the solution. It is expected that the unevenly distributed large particles will cause challenges to precise administration. In addition, very large particles may limit the biodistribution of 22:0Lyso PC in vivo, because the microparticles visible to the naked eye are much larger than cells. When delivered in vivo, large particles may be isolated by the immune system, which may limit the ability of 22:0Lyso PC to reach dendritic cells for super activation. Example 4: Superactivation of murine dendritic cells with a combination of TLR7 / 8 agonists and lipid nanoparticles containing lysophosphatidylcholine (LPC)

[0125] This example describes the superactivation of murine bone marrow-derived dendritic cells (BMDCs) using a combination of a TLR7 / 8 agonist and lipid nanoparticles (LNPs) loaded with superactivating lipids (eg, 22:0 Lyso PC). Materials and methods

[0126] LNP synthesis. LNPs were prepared by combining the following components with or without 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine: (CAS Reg. No. 125146-65-8, referred to herein as “22:0Lyso PC”) (Avanti): 1,2-distearoyl-sn-glycero-3-phosphocholine (CAS Reg. No. 816-94-4, referred to herein as “DSPC”) (Avanti); Cholesterol (Sigman); and 1,2-Dimyristoyl-racemic-glycerol-3-methoxypolyethylene glycol-2000 (CAS Reg. No. 160743-62-4, referred to herein as "DMG-PEG2000") (Avanti). LNPs were prepared without 22:0Lyso PC or loaded with 20% or 40% molar ratio of 22:0Lyso PC to determine whether the 22:0Lyso PC loading could be intentionally varied. Lipid nanoparticles (LNPs) were synthesized using a NanoAssemblr Ignite instrument (Precision Nanosystems). Lipids were first dissolved in ethanol and then, according to the molar percentages shown in Table 4-1, to achieve a total lipid concentration of 12.5 mM. The lipids in ethanol were combined with sodium citrate buffer (pH 4) in a 1:3 volume ratio at a flow rate of 12 mL / min. The LNPs were washed in 10 volumes of phosphate buffered saline (PBS) at pH 7.4 to remove residual ethanol and then concentrated using an Amicon 10K MWCO centrifugal filter.

[0127] LNP characterization. Loading of 22:0Lyso PC in LNPs was assessed using HPLC. LNPs in PBS were frozen at -20°C until quantified. LNPs were dissolved by adding 1 part ethanol to the LNPs in PBS. A seven-point standard curve for 22:0Lyso PC was prepared in 1:1 ethanol:PBS added to match sample preparation. Standards and samples were filtered through a 0.45 μm filter prior to running on the HPLC. HPLC quantification was performed using an Agilent 1260 Infinity II HPLC equipped with a 1260 Infinity II Evaporative Light Scattering Detector. A Luna 5 μm NH2 Samples were detected on a 150X 4.6mm LC column (Phenomenex). Two eluents were used: A, 100% water; and B, 100% acetonitrile. The column was loaded with an initial mobile phase consisting of 5% / 95% A / B, with a gradient reaching 24% / 76% A / B after 2.5 minutes. A shallower gradient was used from 2.5 to 6 minutes, with A / B slowly reaching 25% / 75% over this time frame. A 3-minute post-time was used to return the gradient to the starting conditions before the next sample was run. The flow rate was set to 1 mL / min, and the injection volume for samples and standards was 2.5 μL. An evaporative light scattering detector (ELSD) used an evaporator temperature of 50°C, a nebulizer temperature of 30°C, and a gas flow rate of 0.9 standard liters / minute. Agilent CDS2.6 software was used for HPLC instrument control, data acquisition, and processing.

[0128] The size of LNP was assessed using dynamic light scattering (DLS) on a NanoBrook Omni (Brookhaven) device. Before running on DLS, LNP was diluted 1:10 in PBS. Three 90 second measurements were recorded for each sample. The size of 22:0Lyso PC in PBS was assessed using a Mastersizer 3000 (Malvern) equipped with a Hydro SV small volume dispersion unit set to a rotation speed of 1500 rpm. Five 5 second readings were recorded for each sample.

[0129] Generation of mouse bone marrow-derived FLT3L-DCs. Femurs and tibiae were removed from mice, chopped with scissors and flushed into sterile tubes. The bone marrow suspension was treated with ACK lysis buffer for 1 minute and then passed through a 40 μm cell strainer. The cells were counted and resuspended in a culture medium (I10) consisting of complete IMDM containing 10% FBS, penicillin and streptomycin, and supplements L-glutamine and sodium pyruvate. The cells were then plated at 8 x 10 6 Bone marrow cells / well were plated in P12 plates. Recombinant mouse FLT3L (Miltenyi) was added to the culture at 200 ng / mL. Differentiated cells were used for subsequent assays on day 8. The efficiency of differentiation was monitored by flow cytometry using BD Symphony A3, and CD11c + MHC-II + Cells were routinely above 80% viable.For each experiment, 5 to 15 mice were used to generate bone marrow derived dendritic cells (BMDCs).

[0130] Superactivation of murine bone marrow-derived FLT3L-DCs. BMDCs were harvested on day 8 after differentiation, washed with PBS and cultured at 2 × 10 5 The concentration of individual cells / mL was re-plated in the complete IMDM culture medium (I10) containing FLT3L. Cells were cultured in the presence or absence of 1 μg / mL R848, and then treated with or without 22:0Lyso PC or 82 μM 22:0Lyso PC LNP in PBS. Forty-eight hours after stimulation, supernatants were collected for cytokine measurement. Vitality was measured using CellTiter-Glo assay (Promega), which measures the ATP content from cells. Fifty microliters of CellTiter-Glo reagent were added to the cells of 50 μL. Luminescence was quantified on the SpectraMax M5e plate reader using an integration time of 500 milliseconds. Vitality data were set relative to the control conditions for treating cells with R848. IL-1β and IL-6 cytokine secretion were measured using sandwich ELISA (Invitrogen).

[0131] Quantification of cell viability.Cell viability was assessed by quantifying the presence of ATP as an indicator of metabolically active cells using CellTiter-Glo luminescent cell viability assay (Promega).Metabolic activity was assessed following the manufacturer's instructions.CellTiter-Glo reagent was mixed with cell pellet and remaining supernatant and transferred to white opaque 96-well plates.Luminescence at all wavelengths was measured on Spectramax M5e plate reader (Molecular Devices) using an integration time of 500ms.Percent viability was calculated relative to the DC processed by R848.

[0132] Quantification of IL-1β and IL-6 secretion. ELISA mouse IL-1β and IL-6 kit (Invitrogen) was used to assess IL-1β and IL-6 secretion. ELISA was performed according to the manufacturer's instructions. Spectramax M5e plate reader (Molecular Devices) was used to measure absorbance at 450nm and calibrated at 570nm. In order to determine the IL-1β and IL-6 concentrations in the supernatant, the sample IL-1β or IL-6 concentration was interpolated using a standard curve via 4PL analysis on GraphPad Prism 9 (GraphPad Software). The interpolated results of the samples were then adjusted for any dilution made to the supernatant.

[0133] Superactivation of FLT3L-DCs for migration assays Murine bone marrow-derived dendritic cells (BMDCs) were harvested on day 8 after differentiation, washed with PBS and incubated at 10 x 10 6 The cells were re-plated in I10 containing FLT3L at a concentration of 1 cells / mL. For super activation, 500 μl of R848 was added at a final concentration of 1 μg / mL, and 500 μL of lipid (22:0Lyso PC or 22:0Lyso PC LNP prepared in PBS) was added at a final concentration of 82 μM. The cells were incubated on a tube rotator at 37 ° C for 24 hours. Twenty-four hours after stimulation, the cells were washed with PBS and stained with CFSE (1:1000) for 30 minutes at 37 ° C in the dark. DCs were then counted and 1x10 were injected subcutaneously (SC) at 100 μL / mouse. 6cells. 24 hours after injection, the skin draining lymph nodes (dLN) were dissected from the injected side. Single cell suspensions were prepared and cells were stained with Live / Dead fixable dye (ThermoFisher) in PBS at 4°C for 20 minutes. The cells were then washed again and stained in MACS buffer (PBS with 1% FCS and 2mM EDTA) containing the following fluorescently conjugated antibodies at 4°C for 20 minutes: anti-CD11c and anti-IA / IE (MHC-II). To determine the expression of CD11c in live cells, the expression of + MHC-II + Absolute number of , following the manufacturer's protocol using countBright counting beads (ThermoFisher). Data were acquired on a BD FACS Symphony (Becton-Dickenson). Data were analyzed using FlowJo software (Tree Star). Four mice were used per experimental group. result

[0134] 22:0Lyso PC can be loaded into LNPs. 22:0Lyso PC was effectively incorporated into LNPs containing DSPC, cholesterol and DMG-PEG2000. Using the above LNP synthesis method, 87.4% of the 22:0Lyso PC added during synthesis was recovered from the LNPs and detected by HPLC, as shown in Table 4-1. Table 4-1. Molar concentration percentage of LNP components

[0135] 22:0Lyso PC is more uniform in the LNP formulation. One problem with preparing 22:0Lyso PC in PBS is that 22:0Lyso PC is insoluble, thus resulting in large particles that are not evenly distributed in the solution. The particle diameter is approximately 130 μm ( Fig. 7A ), the polydispersity index is large, indicating a wide range of particle sizes. This particle size is too large to be taken up by cells (e.g., phagocytes) because it is about 10 times larger than the size of the cells. Therefore, these large particles may not reach dendritic cells (or other target cells) in the body. In contrast, when 22:0Lyso PC is incorporated into LNPs, the size of the LNPs is about 50 nm, with the largest particles (unfiltered) having a diameter of less than 1 μm ( Figure 7B ). In addition, the polydispersity index (PDI) of these particles is much smaller, indicating that the suspension is more uniform. At this size, LNP can be easily absorbed by cells. Therefore, it is expected that 22:0Lyso PC has higher bioavailability in vivo. It is expected that the uniformity of 22:0Lyso PC distribution in LNP suspensions translates into more reproducible and more accurate dosing levels.

[0136] 22:0Lyso PC LNP induces mouse DC to secrete IL-1β in vitro. FLT3L-DC is stimulated with only culture medium, empty LNP or 82 μM 22:0Lyso PC in PBS or loaded into LNP. Alternatively, FLT3L-DC is treated with a combination of 1 μg / ml of R848 and 22:0Lyso PC in empty LNP, 22:0Lyso PC LNP or PBS. 48 hours after stimulation, cell supernatants are harvested for ELISA, and cell viability is measured by cell titer glow assay (which measures ATP release levels from cells). When R848 is combined with super activated lipid formulations (22:0Lyso PC in PBS or LNP) or treated with empty LNP, FLT3L DC is viable, as revealed by the percentage of cell viability compared with only R848 ( Fig. 8A In addition, stimulation with R848 in combination with empty LNP or 22:0Lyso PC induced high levels of the pro-inflammatory cytokine IL-6, regardless of whether 22:0Lyso PC was formulated in PBS or LNP ( Figure 8B ). In addition, although R848 and 22:0Lyso PC in PBS did not induce IL-1β secretion from live cells, treatment of DCs with a combination of R848 and 22:0Lyso PC in LNPs did induce IL-1β secretion from live cells ( Figure 8C ), indicating that 22:0Lyso PC in LNP induced DC hyperactivation and had advantages over 22:0Lyso in PBS.

[0137] 22:0Lyso PC LNP induces DC supermigration in vivo. Another sign of superactivation is the ability of superactivating lipids to induce DC supermigration from the skin to the draining lymph nodes (dLN). To evaluate whether 22:0Lyso PC in LNP can induce DC migration, FLT3L-DCs were incubated overnight on a tube rotator with the following: empty LNP, 22:0Lyso PC in LNP, or a combination of R848 with empty LNP, 22:0Lyso PC in LNP, or 22:0Lyso PC in PBS. The next day, the cells were washed and stained with CFSE. Each mouse was injected subcutaneously on the right back with 1x 10 6 cells. 24 hours after injection, dLNs were harvested and single cell suspensions were prepared. dLNs from uninjected mice were used as negative controls. Cells were stained with Live / Dead to identify live cells, CD11c, and MHC-II. CFSE was measured by flow cytometry + 、CD11c + MHC-II +As expected, DCs treated with a combination of R848 and empty LNPs or 22:0Lyso PC LNPs alone did not induce any DC migration from the skin to dLNs ( Fig.8D Similarly, DCs treated with R848 in combination with empty LNPs or R848 in combination with 22:0Lyso PC in PBS did not induce DC migration to dLNs. Interestingly, DCs treated with R848 in combination with 22:0Lyso PC in LNPs enhanced DC migration to dLNs ( Fig.8D ).

[0138] These data prove that, compared with 22:0Lyso PC in aqueous buffer (such as PBS), LNP containing 22:0Lyso PC is an excellent super-activated lipid formulation. Compared with LNP without 22:0Lyso PC and 22:0Lyso PC prepared in PBS, DC treated with 22:0Lyso PC delivered in LNP shows increased IL-1β secretion and increased migration to draining lymph nodes. Therefore, it is expected that compared with the antigen delivered with 22:0Lyso PC in PBS (or with LNP lacking 22:0Lyso PC), when delivered with antigen in vivo, 22:0Lyso PC delivered in LNP leads to more effective de novo T cells (and particularly memory T cells) generation.

Claims

1. A composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a TLR7 / 8 agonist, wherein The acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP).

2. The composition of claim 1, wherein the acyl chain is a C18-C22 acyl chain or a C21-C24 acyl chain.

3. The composition according to claim 1 or claim 2, further comprising an antigen.

4. The composition according to any one of claims 1 to 3, further comprising dendritic cells.

5. A composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and an antigen, wherein The acyl chain is a C21-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP). The composition according to claim 5 , further comprising dendritic cells.

7. The composition according to claim 5 or claim 6, further comprising a TLR7 / 8 agonist.

8. A composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and dendritic cells, wherein The acyl chain is a C21-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP).

9. The composition according to claim 8, further comprising a TLR7 / 8 agonist.

10. The composition of claim 8 or claim 9, further comprising an antigen.

11. The composition of any one of claims 1-10, wherein the acyl chain is a C22 acyl chain.

12. The composition of any one of claims 1-11, wherein the acyl chain is fully saturated.

13. The composition of any one of claims 1-12, wherein the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)].

14. The composition according to any one of claims 1-13, wherein the TLR7 / 8 agonist is a small molecule with a molecular weight of 900 Daltons or less.

15. The composition of claim 14, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound.

16. The composition of claim 15, wherein the TLR7 / 8 agonist comprises resiquimod (R848).

17. The composition of claim 14 or claim 15, wherein the TLR7 / 8 agonist does not inhibit NLR family pyrin domain-containing protein 3 (NLRP3).

18. The composition of claim 13, wherein the LPC comprises LPC(22:0), and the TLR7 / 8 agonist comprises resiquimod (R848).

19. The composition of any one of claims 1-18, wherein the antigen is present in a biological sample obtained from an individual.

20. The composition of claim 19, wherein the biological sample comprises a biopsy tissue.

21. The composition of claim 19, wherein the biological sample comprises cells.

22. The composition of claim 19, wherein the biological sample does not include cells.

23. The composition of claim 19, wherein the biological sample comprises pus from an abscess.

24. The composition of any one of claims 1-23, wherein the antigen comprises a protein antigen.

25. The composition of claim 24, wherein the antigen comprises a tumor antigen.

26. The composition of claim 25, wherein the tumor antigen comprises a synthetic or recombinant neoantigen.

27. The composition of claim 26, wherein the tumor antigen comprises a tumor cell lysate.

28. The composition of claim 24, wherein the antigen comprises a microbial antigen, and the microbial antigen comprises one or more of a viral antigen, a bacterial antigen, a protozoan antigen, and a fungal antigen.

29. The composition of claim 28, wherein the microbial antigen comprises a purified or recombinant surface protein.

30. The composition of claim 28, wherein the microbial antigen comprises an inactivated whole virus.

31. The composition of any one of claims 1-30, wherein the composition comprises liposomes.

32. The composition of any one of claims 1-31, wherein the composition does not comprise lipopolysaccharide (LPS) or monophosphoryl lipid A (MPLA).

33. The composition of any one of claims 1-32, wherein the composition does not comprise oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphatidylcholine (oxPAPC) or species of oxPAPC.

34. The composition of claim 33, wherein the composition does not contain 2-[[(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-hexadecanoyloxypropyloxy]-hydroxyphosphoryl]oxyethyl-trimethylazonium (HOdiA-PC), [(2R)-2-[(E)-7-carboxy-5-hydroxyhept-6-enoyl]oxy-3-hexadecanoyloxypropyl]-hydroxyphosphoryl]oxyethyl-trimethylazonium (HOdiA-PC), [(2R)-2-[(E)-7-carboxy-5-oxohept-6-enoyl]oxy-3-hexadecanoyloxypropyl]-2-(trimethylazonium)ethylphosphoryl]oxyethyl-trimethylazonium ester (KOdiA-PC), 1-palmitoyl-2-(5-hydroxy-8-oxo-octenoyl)-sn-glycero-3-phosphatidylcholine (HOOA-PC), 2-[[(2R)-2-[(E)-5,8-dioxooct-6-enoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylammonium (KOOA-PC), [(2R)-3-hexadecanoyloxy-2-(5-oxopentanoyloxy)-sn-glycero-3-phosphatidylcholine (HOOA-PC), )propyl] 2-(trimethylazonium)ethyl phosphate (POVPC), [(2R)-2-(4-carboxybutyryloxy)-3-hexadecanoyloxypropyl] 2-(trimethylazonium)ethyl phosphate (PGPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[2-[(Z)-oct-2-enyl]-5-oxocyclopent-3-en-1-ylidene]methyl]oxiran-2-yl]butyryloxy]propyl] 2-(trimethylazonia)ethyl phosphate (PECPC), [(2R)-3-hexadecanoyloxy-2-[4-[3-[(E)-[3-hydroxy-2-[(Z)-oct-2-enyl]-5-oxocyclopentylidene]methyl]oxiran-2-yl]butanoyloxy]propyl]2-(trimethylazonia)ethyl phosphate (PEIPC) and / or 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzePC).

35. The composition of any one of claims 1-34, further comprising an adjuvant, wherein the adjuvant comprises an aluminum salt adjuvant, a squalene-in-water emulsion, a saponin, or a combination thereof.

36. A pharmaceutical formulation comprising the composition according to any one of claims 1-35 and a pharmaceutically acceptable excipient.

37. A method for producing hyperactivated dendritic cells, the method comprising contacting the dendritic cells with an effective amount of a composition comprising isolated lysophosphatidylcholine (LPC) having a single C13-C22 acyl chain or a C13-C24 acyl chain, at least one additional lipid, and a TLR7 / 8 agonist to produce hyperactivated dendritic cells, wherein The hyperactivated dendritic cells secrete IL-1β without undergoing pyroptosis. The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP).

38. The method of claim 37, wherein the dendritic cells are contacted ex vivo with the composition of any one of claims 1-35 or the formulation of claim 36.

39. The method of claim 37, wherein the dendritic cells are contacted with the formulation of claim 36 in vivo.

40. A pharmaceutical formulation comprising at least 10 3 , 10 4 , 10 5 or 10 6 A hyperactivated dendritic cell produced by the method according to claim 38 and a pharmaceutically acceptable excipient.

41. A method of stimulating an immune response to an antigen, the method comprising administering to an individual in need thereof an effective amount of the formulation of claim 36 to stimulate the immune response to the antigen.

42. A method of treating cancer, comprising administering to an individual in need thereof an effective amount of the formulation of claim 36 to treat the cancer.

43. A method of inhibiting abnormal cell proliferation, the method comprising administering to an individual in need thereof an effective amount of the formulation of claim 36 to inhibit abnormal cell proliferation.

44. A method of treating an infectious disease, the method comprising administering to an individual in need thereof an effective amount of the formulation of claim 36 to treat the infectious disease.

45. Use of the formulation according to claim 36 for inducing an immune response against the antigen in an individual in need thereof.

46. ​​Use of the formulation of claim 36 for inducing an anti-tumor immune response in an individual in need thereof, wherein the individual bears or has had a tumor.

47. Use of the formulation of claim 36 for inducing an anti-microbial immune response in an individual in need thereof, wherein the individual is infected with the microorganism or has not been exposed to the microorganism.

48. The composition, formulation, method or use of any one of claims 19-47, wherein the individual is a mammalian subject.

49. The composition, formulation, method or use of any one of claims 19-47, wherein the individual is a human subject.

50. A method of preparing an immunogenic composition, the method comprising: a) obtaining a suspension rich in tumor cells from the tumor; b) lysing cells from the tumor cell-enriched suspension to obtain a tumor cell lysate; as well as c) contacting the tumor cell lysate with a composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a toll-like receptor 7 / 8 (TLR7 / 8) agonist to obtain the immunogenic composition, wherein The acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP).

51. The method of claim 50, wherein step a) comprises depleting leukocytes from the tumor cell-enriched suspension, optionally wherein the leukocytes are depleted by negative selection using an anti-CD45 antibody.

52. The method of claim 50 or claim 51 , wherein in step b) the cells are lysed by one or more freeze-thaw cycles.

53. The method of any one of claims 50-52, wherein the acyl chain is a fully saturated C18-C22 acyl chain or a fully saturated C18-C24 acyl chain.

54. The method of claim 53, wherein the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)].

55. The method of any one of claims 50-54, wherein the TLR7 / 8 agonist is a small molecule having a molecular weight of 900 Daltons or less.

56. The method of claim 55, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound.

57. The method of claim 56, wherein the TLR7 / 8 agonist comprises resiquimod (R848).

58. The method of claim 55 or claim 56, wherein the TLR7 / 8 agonist does not inhibit NLR family pyrin domain-containing protein 3 (NLRP3).

59. The method of claim 54, wherein the LPC comprises LPC(22:0) and the TLR7 / 8 agonist comprises resiquimod (R848).

60. The method according to any one of claims 50-59, further comprising: Prior to step a), a sample is obtained from said tumor from a mammalian subject suffering from cancer, and said cell suspension is prepared from said sample.

61. An immunogenic composition prepared by the method of any one of claims 50-60.

62. A method for eliciting an anti-cancer immune response, the method comprising: An effective amount of the immunogenic composition of claim 61 is administered to a mammalian subject having cancer.

63. The method of claim 62, wherein the anti-cancer immune response comprises a cellular immune response.

64. The method of claim 63, wherein the anti-cancer immune response comprises cancer antigen-induced IL-1β secretion and / or CD8+ T lymphocyte activation.

65. The method of any one of claims 62-64, wherein the cancer is a non-hematological cancer.

66. The method of claim 65, wherein the non-hematological cancer is a carcinoma, a sarcoma, or a melanoma.

67. The method of any one of claims 62-64, wherein the cancer is lymphoma.

68. A method of treating cancer, the method comprising: a) preparing an immunogenic composition comprising a tumor cell lysate, isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a toll-like receptor 7 / 8 (TLR7 / 8) agonist, wherein The tumor cell lysate is or has been prepared from a tumor sample obtained from a mammalian subject suffering from cancer, The acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP); and b) administering an effective amount of the immunogenic composition to the subject.

69. The method of any one of claims 62-68, wherein the acyl chain is a fully saturated C18-C22 acyl chain or a fully saturated C18-C24 acyl chain.

70. The method of claim 68, wherein the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)].

71. The method of any one of claims 62-70, wherein the TLR7 / 8 agonist is a small molecule having a molecular weight of 900 Daltons or less.

72. The method of claim 71, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound.

73. The method of claim 72, wherein the TLR7 / 8 agonist comprises resiquimod (R848).

74. The method of claim 70, wherein the LPC comprises 22:0 LPC and the TLR7 / 8 agonist comprises resiquimod (R848).

75. The method of any one of claims 68-74, further comprising administering to the subject an effective amount of an additional therapeutic agent.

76. The method of claim 75, wherein the additional therapeutic agent comprises one or more of the group consisting of an immune checkpoint inhibitor, an anti-tumor agent, and radiation therapy.

77. A composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid, and a pathogen recognition receptor (PRR) agonist, wherein The acyl chain is a C13-C22 acyl chain or a C13-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP).

78. The composition of claim 77, wherein the PRR agonist is an agonist of a toll-like receptor (TLR), a NOD-like receptor (NLR), a RIG-I-like receptor (RLR), or a C-type lectin receptor (CLR).

79. The composition of claim 77, wherein the PRR agonist is an agonist of the cytoplasmic DNA sensor (CDS) or stimulator of IFN genes (STING).

80. The composition of claim 77, wherein the PRR agonist comprises one or more of R848, TL8-506, LPS, Pam2CSK4, and ODN 2336.

81. The composition of any one of claims 77-80, further comprising an antigen.

82. The composition of any one of claims 77-81, further comprising dendritic cells.

83. A pharmaceutical formulation comprising a composition according to any one of claims 77-82 and a pharmaceutically acceptable excipient.

84. A pharmaceutical formulation comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a pharmaceutically acceptable excipient, wherein The acyl chain is a C21-C24 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, and The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP).

85. The pharmaceutical formulation of claim 83 or claim 84, wherein the acyl chain is a fully saturated C22 acyl chain.

86. The pharmaceutical formulation of claim 85, wherein the LPC comprises 1-behenoyl-2-hydroxy-sn-glycero-3-phosphocholine [LPC(22:0)].

87. A composition for superactivating human dendritic cells, the composition comprising isolated lysophosphatidylcholine (LPC) having a single acyl chain, at least one additional lipid and a pathogen recognition receptor (PRR) agonist, wherein The acyl chain is a C22 acyl chain, The at least one additional lipid is selected from the group consisting of ionizable lipids, cationic lipids, additional phospholipids, pegylated lipids, structured lipids, and mixtures thereof, The LPC and the at least one additional lipid are part of a lipid nanoparticle (LNP), and The composition is effective for achieving higher levels of dendritic cell hyperactivation than a comparative composition comprising PGPCs in place of the LPCs.

88. The composition of claim 87, wherein the higher level of dendritic cell hyperactivation comprises inducing IL-1β secretion from the human dendritic cells in vitro at a level that is at least 2, 3, or 4 times higher when contacted with the composition comprising the LPC and the PRR agonist than when contacted with the comparative composition comprising the PGPC and the PRR agonist, wherein the PRR agonist is LPS.

89. The composition of claim 88, wherein the concentration of the LPC and the concentration of the PGPC are the same concentration ranging from about 10 μM to about 80 μM, and the LPS is present in both the composition and the comparative composition at a concentration of 1 μg / ml.

90. The composition of claim 88, wherein the higher level of dendritic cell hyperactivation comprises a lipid activity index for IL-1β secretion from the human dendritic cells of the composition comprising the LPC and the PRR agonist that is at least 4, 5, or 6 times higher in activity units than the lipid activity index of the comparative composition comprising the PGPC and the PRR agonist.

91. The composition, formulation, method or use of any one of claims 19-47, wherein the individual is a canine subject.

92. The composition, formulation, method or use of any one of claims 60-90, wherein the mammalian subject is a human patient.

93. The composition, formulation, method or use of any one of claims 60-90, wherein the mammalian subject is a non-human patient.

94. The composition, formulation, method or use of any one of claims 60-90, wherein the mammalian subject is a canine patient.

95. The composition, formulation, method or use of any one of claims 1-90 or 92, wherein the dendritic cells are human dendritic cells.

96. The composition, formulation, method or use of any one of claims 1-91 or 94, wherein the dendritic cells are canine dendritic cells.

97. The composition, formulation, method or use of claim 95 or claim 96, wherein the dendritic cells are present in a composition comprising peripheral blood mononuclear cells (PBMCs).

98. The composition, formulation, method or use of any one of claims 37-49 or claim 91, wherein the hyperactivated dendritic cells secrete one or both of IFNγ and TNFα.

99. The composition, formulation, method or use of any one of claims 1-98, wherein the at least one additional lipid comprises one or both of an additional phospholipid and a structural lipid, optionally wherein the additional phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and the structural lipid comprises cholesterol.

100. The composition, formulation, method or use of claim 99, wherein the at least one additional lipid comprises a PEGylated lipid, optionally wherein the PEGylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoylglycerol [DMG].

101. according to the composition, formulation, method or use described in claim 99 or claim 100, wherein the at least one additional lipid comprises an ionizable lipid, optionally wherein the ionizable lipid comprises 4-(dimethylamino)-butyric acid, (10Z, 13Z)-1-(9Z, 12Z)-9,12-octadecadien-1-yl-10,13-nonadecadien-1-yl ester (DLin-MC3-DMA) or its analog or derivative.

102. A composition comprising lipid nanoparticles (LNPs), wherein the LNPs comprise a first phospholipid and at least one lipid, wherein the at least one lipid is selected from an ionizable lipid, a second phospholipid, a pegylated lipid, a structured lipid, and a mixture thereof, wherein the first phospholipid comprises a lysophosphatidylcholine (LPC) having a single acyl chain, and the acyl chain is a C13-C24 acyl chain.

103. A composition comprising lipid nanoparticles (LNPs), wherein the LNPs comprise a first phospholipid, an ionizable lipid, a second phospholipid, a pegylated lipid, and a structural lipid, wherein the first phospholipid comprises a lysophosphatidylcholine (LPC) having a single acyl chain, and the acyl chain is a C13-C24 acyl chain.

104. The composition of any one of claims 1-103, wherein the ionizable lipid comprises: i) 8-[(2-hydroxyethyl)[6-oxo-6-(undecanyloxy)hexyl]amino]octanoic acid, 1-octylnonyl ester (SM-102) or its analogs or derivatives; and / or 6-((2-hexyldecanoyl)oxy)-N-(6-((2-hexyldecanoyl)oxy)hexyl)-N-(4-hydroxybutyl)hexane-1-ammonium (ALC-0315) or its analogs or derivatives; or ii) (6Z,9Z,28Z,31Z)-heptatriacontane-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butyrate (DLin-MC3-DMA) or an analogue or derivative thereof.

105. The composition of any one of claims 1-104, wherein the PEGylated lipid is selected from PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and combinations thereof.

106. The composition of any one of claims 1-104, wherein the PEGylated lipid comprises polyethylene glycol [PEG] 2000 dimyristoylglycerol [DMG].

107. The composition of any one of claims 1-106, wherein the structured lipid is selected from the group consisting of cholesterol, coprostanol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and combinations thereof.

108. The composition of any one of claims 1-106, wherein the structured lipid comprises cholesterol.

109. A composition according to any one of claims 1-108, wherein the additional phospholipid or the second phospholipid comprises a hydrophilic head portion selected from phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidic acid, 2-lysophosphatidylcholine and sphingomyelin.

110. A composition according to claims 1-108, wherein the additional phospholipid or the second phospholipid comprises one or more fatty acid tail moieties, and the one or more fatty acid tail moieties are selected from lauric acid, myristic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, erucic acid, arachidic acid, arachidonic acid, phytanic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid and docosahexaenoic acid.

111. The composition of any one of claims 1-108, wherein the additional phospholipid or the second phospholipid is selected from: 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-Dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine, 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine, 1,2-Dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-Diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine, 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-Diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-Dioleoyl-sn-glycero-3-phospho-racemic-(1-glycerol) sodium salt (DOPG), Sphingomyelin and Its combination.

112. The composition of any one of claims 1-108, wherein the additional phospholipid or the second phospholipid comprises 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

113. The composition of any one of claims 1-112, wherein the at least one additional lipid comprises: i) a cationic lipid, and includes or further includes ii) a neutral or anionic lipid.

114. according to the composition described in claim 113, wherein said cationic lipid comprises one or both of following: i) 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) or its analogs or derivatives; and ii) 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) or an analogue or derivative thereof.

115. The composition of claim 113 or claim 114, wherein the neutral or anionic lipid comprises: i) 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE) or an analogue or derivative thereof; and / or ii) cholesterol or its analogs or derivatives; and / or iii) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or an analogue or derivative thereof.

116. The composition of any one of claims 102-115, wherein the acyl chain of the LPC is a C21-C24 acyl chain.

117. A composition according to any one of claims 102-115, wherein the acyl chain of the LPC is a C22 acyl chain.

118. The composition of any one of claims 102-117, wherein the composition further comprises a TLR7 / 8 agonist.

119. The composition of claim 118, wherein the TLR7 / 8 agonist comprises an imidazoquinoline compound.

120. The composition of claim 119, wherein the TLR7 / 8 agonist comprises resiquimod (R848).

121. The composition of claim 119, wherein the LPC comprises LPC(22:0) and the TLR7 / 8 agonist comprises resiquimod (R848).

122. The composition of any one of claims 102-121, wherein the composition further comprises an antigen.

123. The composition of claim 122, wherein the antigen is a tumor antigen or a neoantigen.

124. The composition of claim 122, wherein the antigen is a microbial antigen, optionally wherein the microbial antigen is a viral antigen, a bacterial antigen, a protozoan antigen, or a fungal antigen.

125. The composition, formulation, method or use of any one of claims 1-124, wherein the composition does not comprise isolated mRNA.

126. The composition, formulation, method or use of any one of claims 1-125, wherein the LNP has an effective diameter of less than about 500 nanometers, optionally about 5 to about 500 nanometers, optionally about 10 to about 400 nanometers, optionally about 20 to about 300 nanometers, or optionally about 25 to about 250 nanometers.

127. The composition, formulation, method or use of claim 126, wherein the LNP has an effective diameter of less than about 250 nanometers.

128. The composition, formulation, method or use of claim 127, wherein the LNP has an effective diameter of less than about 125 nanometers.

129. The composition, formulation, method or use of claim 128, wherein the LNP has an effective diameter of about 10 to about 110 nanometers.

130. The composition, formulation, method or use of any one of claims 1-129, wherein the composition does not comprise a surfactant.

Citation Information

Patent Citations

  • Method and apparatus for maintaining the concentration of a liquid developing solution, in particular for a developing process using the semi-wet method

    EP0002020A1

  • Wet-end molding method and molded product

    EP0108381A1

  • Spinal implant system and methods of use

    US20220071664A1